{"response_id": "deepseek-v3.2:cloud|ADMET-PEP-08", "question_id": "ADMET-PEP-08", "pair_id": "ADMET-08", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "Some cyclic peptides (~1000–1200 Da) can show measurable oral exposure despite violating Rule-of-Five guidelines. Name three molecular features that enable this and explain the mechanism in terms of effective polarity.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Three molecular features that enable measurable oral exposure in cyclic peptides despite violating Rule-of-Five guidelines are:\n\n1. **N-Methylation of backbone amides**  \n   *Mechanism*: Reduces the number of hydrogen bond donors (HBDs) and increases lipophilicity. This decreases the effective polarity by preventing solvation and hydrogen bonding with water, thereby enhancing passive membrane permeability.\n\n2. **Intramolecular hydrogen bonding**  \n   *Mechanism*: In cyclic peptides, constrained conformations (e.g., β-turns) can form internal hydrogen bonds that shield polar groups from the solvent. This reduces the effective polarity by presenting a less polar surface to the aqueous environment, mimicking the \"chameleon\" behavior of some orally bioavailable peptides.\n\n3. **Hydrophobic side chains and shielding**  \n   *Mechanism*: Incorporation of hydrophobic residues (e.g., N-alkylated amino acids) or clustering of aromatic side chains can create transiently shielded polar surfaces. This lowers the effective polarity in a dynamic manner, facilitating diffusion across lipid membranes.\n\n**Key Concept**: Effective polarity is lowered not by simply removing polar groups, but by reducing their *availability* to interact with water or membranes through conformational constraints and intramolecular interactions. Cyclic peptides often achieve this more efficiently than linear analogs due to preorganization.", "latency_ms": 9830, "timestamp": "2026-02-09T11:41:20.241484+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|OPT-PEP-04", "question_id": "OPT-PEP-04", "pair_id": "OPT-04", "category": "Optimization Approaches", "domain": "peptide", "question_text": "How can Bayesian optimization be applied to peptide sequences using embeddings, and what does EI do in that setting?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Bayesian optimization (BO) can be applied to peptide sequence optimization by using embeddings to convert discrete sequences into a continuous search space. Here's the typical pipeline:\n\n1.  **Representation**: Each peptide sequence (e.g., \"ACDEF\") is mapped to a fixed-dimensional continuous vector using an embedding method. Common approaches include:\n    *   Learned embeddings from protein language models (e.g., ESM, ProtBERT).\n    *   Hand-crafted feature vectors (e.g., physicochemical properties, amino acid indices).\n    *   One-hot encodings followed by a dimensionality reduction technique like PCA.\n\n2.  **Surrogate Model**: A probabilistic model, typically a Gaussian Process (GP), is trained on the embedding vectors of evaluated sequences and their corresponding experimental activity scores (e.g., binding affinity, stability).\n\n3.  **Acquisition Function**: This function uses the surrogate model's predictions (mean and uncertainty) to propose the most promising *unseen* sequence to evaluate next. **Expected Improvement (EI)** is the most common acquisition function in this setting.\n\n### What Expected Improvement (EI) Does\n\nIn the context of peptide optimization, **EI quantifies the potential utility of evaluating a new candidate sequence by balancing exploration (sampling in uncertain regions of the embedding space) and exploitation (sampling near the best-known sequence)**.\n\nMathematically, for a candidate peptide embedding **x**, EI calculates the *expected value* of how much its predicted property \\( f(x) \\) will exceed the current best observed value \\( f(x^+) \\):\n\n\\[\nEI(x) = \\mathbb{E} [\\max(f(x) - f(x^+), 0)]\n\\]\n\nUnder a GP surrogate, this has a closed-form solution using the predicted mean \\( \\mu(x) \\), uncertainty \\( \\sigma(x) \\), and the standard normal CDF and PDF.\n\n**In practice, EI ranks all candidate peptide embeddings by this score. The sequence whose embedding has the highest EI is selected for the next costly wet-lab experiment because it offers the best statistical chance of improving upon the current best result.**\n\n**Example**: If the best peptide found so far has an IC₅₀ of 100 nM, EI might favor a new sequence predicted to have a mean IC₅₀ of 10 nM with high uncertainty (e.g., 95% CI: 1 nM to 1000 nM) over one predicted at 20 nM with very low uncertainty. The high reward potential outweighs the risk.\n\n**Key Advantage**: This data-efficient strategy minimizes the number of expensive experiments needed to discover high-performing peptides by intelligently selecting which sequence to synthesize and test next.", "latency_ms": 33926, "timestamp": "2026-02-09T11:41:57.168748+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ADMET-SM-06", "question_id": "ADMET-SM-06", "pair_id": "ADMET-06", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "A candidate has TPSA = 140 Å², HBD = 3, and is a P-gp substrate. Name two design strategies that can increase oral absorption and briefly explain the mechanism.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Two design strategies to increase oral absorption for this candidate are:\n\n1. **Reduce topological polar surface area (TPSA) and hydrogen bond donors (HBD):**  \n   Lowering TPSA (e.g., below 120 Å²) and HBD decreases polarity and hydrogen-bonding capacity, enhancing passive transcellular diffusion across the intestinal epithelium. This improves permeability, as compounds with TPSA < 140 Å² and HBD ≤ 5 typically show better absorption.\n\n2. **Modify structure to reduce P-glycoprotein (P-gp) recognition:**  \n   Altering substituents—such as masking hydrogen bond donors or introducing bulky, lipophilic groups—can decrease affinity for P-gp. This reduces efflux pumping of the drug back into the gut lumen, increasing net absorption.", "latency_ms": 24216, "timestamp": "2026-02-09T11:42:24.386611+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ADMET-SM-07", "question_id": "ADMET-SM-07", "pair_id": "ADMET-07", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "Assume hepatic blood flow Qh ≈ 90 L/h. A drug has hepatic clearance CLh = 60 L/h. Compute the extraction ratio E and state whether clearance is more likely flow-limited or capacity/fu-limited.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "The extraction ratio \\(E\\) is calculated as:\n\n\\[\nE = \\frac{CL_h}{Q_h} = \\frac{60 \\, \\text{L/h}}{90 \\, \\text{L/h}} = 0.667 \\quad \\text{(approximately } \\frac{2}{3}\\text{)}.\n\\]\n\nWith \\(E = 0.667\\), the drug has a high extraction ratio (", "latency_ms": 18326, "timestamp": "2026-02-09T11:42:45.713397+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|SAR-SM-01", "question_id": "SAR-SM-01", "pair_id": "SAR-01", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A ligand’s para-substituent on a phenyl ring points into a hydrophobic subpocket and sits ~3.2 Å from a protein backbone carbonyl oxygen (geometry compatible with a halogen bond). If the para-methyl analog has IC50 = 200 nM, what is the most likely potency change when replacing para-CH3 with para-Cl, and what is the mechanistic rationale?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "", "latency_ms": 21855, "timestamp": "2026-02-09T11:45:31.814519+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "deepseek-v3.2:cloud|SAR-SM-08", "question_id": "SAR-SM-08", "pair_id": "SAR-08", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A lead compound binds in a folded conformation. You add a gem-dimethyl group adjacent to the folding hinge (Thorpe–Ingold effect) to bias the folded conformation. If conformational preorganization improves binding free energy by ~1.0 kcal/mol, approximately what potency change (fold) would you expect at 298 K, and why?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Adding a gem-dimethyl group to bias the folded conformation via the Thorpe–Ingold effect improves binding free energy by approximately −1.0 kcal/mol. At 298 K, where RT ≈ 0.592 kcal/mol, this ΔΔG corresponds to a potency increase by a factor of exp(1.0 / 0.592) ≈ 5.4-fold. Thus, the expected potency change is approximately 5- to 6-fold.", "latency_ms": 15646, "timestamp": "2026-02-09T11:45:50.461503+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|GEN-PEP-06", "question_id": "GEN-PEP-06", "pair_id": "GEN-06", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "Name two generation-time techniques that increase diversity of generated peptide sequences and one quantitative diversity metric commonly used for sequences.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Two generation-time techniques that enhance the diversity of generated peptide sequences are:\n\n1. **High-temperature sampling**: In probabilistic models (e.g., neural networks), increasing the temperature parameter flattens the output probability distribution, promoting more random and diverse sequence generation. For example, temperatures >1.0 increase diversity compared to greedy sampling.\n\n2. **Diverse beam search**: This modifies standard beam search by incorporating diversity penalties, such as Hamming distance constraints, to ensure the top-k generated sequences are distinct, thereby increasing variety.\n\nOne quantitative diversity metric commonly used for sequences is:\n\n- **Average pairwise Hamming distance**: It measures the average number of positional differences between all pairs of sequences in a set, providing a straightforward numerical assessment of diversity. For instance, a higher average Hamming distance indicates greater sequence variation.", "latency_ms": 27695, "timestamp": "2026-02-09T11:46:21.156972+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|OPT-PEP-06", "question_id": "OPT-PEP-06", "pair_id": "OPT-06", "category": "Optimization Approaches", "domain": "peptide", "question_text": "A peptide binds both a target receptor and a homolog. Only the target has a unique Asp near the interface; the homolog has Asn at that position. What sequence modification strategy is most likely to improve selectivity, and why?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Introduce a basic residue (e.g., Arg or Lys) into the peptide sequence to form a salt bridge with the target's Asp. This electrostatic interaction is favorable only with the charged Asp, not with the neutral Asn in the homolog, thereby enhancing selectivity for the target.", "latency_ms": 18100, "timestamp": "2026-02-09T11:46:42.258198+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|OPT-SM-02", "question_id": "OPT-SM-02", "pair_id": "OPT-02", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "In multi-parameter optimization (MPO) for small molecules, how does a weighted desirability function combine objectives, and what is the limitation when objectives conflict?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "A weighted desirability function in MPO transforms each objective (e.g., potency, solubility) into a desirability score (d_i) ranging from 0 (unacceptable) to 1 (ideal), using functions that define acceptable thresholds or targets. These scores are combined via a weighted geometric mean:  \nD = (∏ d_i^{w_i})^{1/∑ w_i},", "latency_ms": 24744, "timestamp": "2026-02-09T11:47:10.003113+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ASSAY-PEP-04", "question_id": "ASSAY-PEP-04", "pair_id": "ASSAY-04", "category": "Assay Interpretation", "domain": "peptide", "question_text": "A peptide is degraded by a protease with apparent first-order rate constant k = 0.023 min^-1 (measured under pseudo-first-order conditions). Compute the degradation half-life and interpret what this means for a 2-hour incubation assay.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "The degradation half-life is approximately 30 minutes, calculated using the formula \\( t_{1/2} = \\ln(2) / k \\), where \\( k = 0.023 \\, \\text{min}^{-1} \\).\n\nFor a 2-hour (120-minute) incubation assay, this half-life corresponds to about 4 half-lives, meaning only ~6% of the original peptide remains intact. Such extensive degradation could significantly impact assay results, potentially necessitating shorter incubation times, the use of protease inhibitors, or correction for degradation kinetics.", "latency_ms": 15957, "timestamp": "2026-02-09T11:47:28.960966+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ADMET-PEP-03", "question_id": "ADMET-PEP-03", "pair_id": "ADMET-03", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "Name three common drivers of peptide immunogenicity (anti-drug antibody risk) and two mitigation strategies used in therapeutic peptide design.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "**Three Common Drivers of Peptide Immunogenicity:**\n\n1.  **Sequence-Derived T-cell Epitopes:** The presence of peptide sequences that can be bound by MHC class II molecules and recognized by helper T-cells is a primary driver. This is especially likely if the peptide contains **non-human or novel sequences** (e.g., from bacterial or venom origins) or **aggregation-prone regions** that create neoeptopes.\n2.  **Aggregation:** Peptide aggregates act as multivalent scaffolds that can cross-link B-cell receptors and are more readily taken up by antigen-presenting cells, potently stimulating both B- and T-cell responses. Even low levels (e.g., >1%) of soluble aggregates can significantly increase immunogenicity risk.\n3.  **Chemical Degradation/Modifications:** Post-translational modifications (PTMs) like **deamidation** (e.g., asparagine to isoaspartate), **oxidation** (e.g., methionine), or **glycation** can create new epitopes not subject to immune tolerance. For example, deamidation at a common N-G sequence motif is a frequent culprit.\n\n**Two Key Mitigation Strategies:**\n\n1.  **Sequence Humanization/De-immunization:** Using *in silico* tools to identify and eliminate predicted T-cell epitopes by substituting non-essential amino acids with human-like residues. For example, replacing a non-critical arginine with lysine might remove an MHC-binding motif while preserving activity.\n2.  **Conjugation with Polyethylene Glycol (PEGylation):** Covalently attaching PEG chains shields the peptide from immune recognition by:\n    *  Sterically hindering proteolytic degradation and uptake by antigen-presenting cells.\n    *  Reducing aggregation propensity.\n    *  Increasing hydrodynamic size, which can limit lymphatic trafficking.", "latency_ms": 19180, "timestamp": "2026-02-09T11:47:51.141485+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|GEN-SM-01", "question_id": "GEN-SM-01", "pair_id": "GEN-01", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "In SMILES-based molecular generation, name three necessary validity conditions a generated string must satisfy to correspond to a chemically valid molecule.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "In SMILES-based molecular generation, a generated string must satisfy the following three necessary validity conditions to correspond to a chemically valid molecule:\n\n1. **Syntactic validity**: The string must conform to the formal SMILES grammar rules, including correct use of atom symbols (e.g., C, O, N), bond types (e.g., -, =, #), parentheses for branching, and matching digits for ring closures.\n2. **Valence validity**: All atoms must adhere to standard chemical valence rules—for example, carbon must have four bonds, nitrogen typically three or five in certain states, and oxygen two—without exceeding their allowed bonding capacities.\n3. **Connectivity validity**: The molecular graph must be fully connected, meaning all atoms are linked through bonds without isolated fragments, ensuring a single, coherent structure.\n\nThese conditions ensure that the SMILES string is both parsable and represents a plausible chemical entity.", "latency_ms": 19078, "timestamp": "2026-02-09T11:48:13.220183+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ADMET-SM-04", "question_id": "ADMET-SM-04", "pair_id": "ADMET-04", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "A small molecule has systemic clearance CL = 30 L/h and volume of distribution Vd = 300 L in humans. Estimate the terminal half-life and interpret what a Vd this large typically implies about tissue distribution.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "The terminal half-life is approximately 6.9 hours, calculated using the formula \\( t_{1/2} = \\frac{0.693 \\times V_d}{CL} \\).\n\nA volume of distribution (Vd) of 300 L is much larger than total body water (~42 L), indicating extensive tissue distribution. This typically suggests high lipophilicity, strong tissue binding, or both, allowing the drug to accumulate in tissues beyond the plasma compartment.", "latency_ms": 11397, "timestamp": "2026-02-09T11:48:27.617857+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|GEN-SM-02", "question_id": "GEN-SM-02", "pair_id": "GEN-02", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "Why do graph-based molecular generators often yield higher validity rates than naive character-level SMILES generators?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Graph-based molecular generators typically achieve near 100% structural validity, while character-level SMILES generators often achieve 60–90% validity. This difference stems from their fundamental representations:\n\n1.  **Inherent Representation:** Graph-based generators directly manipulate atoms and bonds, enforcing chemical rules (e.g., valency constraints) during the generation process. Each step adds a valid atom or bond within the context of the existing structure.\n2.  **Sequential Ambiguity:** SMILES generators output a linear string character-by-character. A single misplaced bracket, ring closure digit, or invalid character can render the entire string syntactically or chemically invalid. The model must learn complex, long-range dependencies in the syntax from data alone.\n\nIn essence, graph-based methods build molecules using their natural topology, which inherently respects chemical rules. SMILES generators must learn these rules implicitly from sequence data, making them more prone to syntactic errors. However, graph-based methods are often more computationally expensive.", "latency_ms": 9305, "timestamp": "2026-02-09T11:48:39.923833+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ASSAY-SM-07", "question_id": "ASSAY-SM-07", "pair_id": "ASSAY-07", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "Three analogs have (IC50 nM, kinetic solubility µM): A(30, 2), B(80, 50), C(20, 0.5). If you require IC50 ≤ 50 nM and solubility ≥ 5 µM for the next round, which analog best meets criteria and what is the most logical next experimental step?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "", "latency_ms": 20114, "timestamp": "2026-02-09T11:51:19.195049+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "deepseek-v3.2:cloud|SAR-PEP-01", "question_id": "SAR-PEP-01", "pair_id": "SAR-01", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide ligand has a Leu side chain that inserts into a hydrophobic subpocket adjacent to an aromatic residue that can support edge-to-face π interactions. If the Leu-containing peptide has Kd = 200 nM, what is the most likely binding change when substituting that Leu with Phe, and why?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Substituting Leu with Phe is likely to decrease Kd (improve binding affinity), potentially to a range of 10–50 nM, because the aromatic side chain of Phe can engage in favorable edge-to-face π interactions with the adjacent aromatic residue, adding stabilization energy beyond the hydrophobic interactions provided by Leu. This assumes the hydrophobic subpocket accommodates the slightly larger benzyl group without steric clash.", "latency_ms": 18692, "timestamp": "2026-02-09T11:51:40.888300+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|OPT-PEP-08", "question_id": "OPT-PEP-08", "pair_id": "OPT-08", "category": "Optimization Approaches", "domain": "peptide", "question_text": "In designing an affinity-maturation library for a peptide, why do you typically limit the number of mutated positions per variant, and how does this relate to epistasis and library size?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "In affinity maturation, the number of mutated positions per variant is typically limited to 3–6 to maintain a practical library size and manage epistatic interactions. \n\n- **Library Size Control**: The total number of variants scales exponentially with the number of mutated positions. For example, randomizing 5 positions with 20 amino acids each yields \\(20^5 = 3.2 \\times 10^6\\) variants, which is screenable with high-throughput methods. In contrast, randomizing 10 positions leads to \\(20^{10} \\approx 10^{13}\\) variants, which is prohibitively large for most screens.\n- **Epistasis Management**: Epistasis (where mutation effects depend on genetic background) is common in peptides. Limiting mutations per variant allows stepwise identification of beneficial changes, reducing the risk of missing synergistic combinations or including detrimental ones. Initial screens often focus", "latency_ms": 29124, "timestamp": "2026-02-09T11:52:13.013125+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ADMET-PEP-04", "question_id": "ADMET-PEP-04", "pair_id": "ADMET-04", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "A therapeutic peptide has systemic clearance CL = 12 L/h and Vd = 4 L in humans. Estimate the terminal half-life and interpret what a Vd near 3–5 L typically implies about distribution.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "The terminal half-life is approximately 0.23 hours (14 minutes), calculated using t₁/₂ = (0.693 × Vd) / CL = (0.693 × 4 L) / (12 L/h).\n\nA volume of distribution (Vd) of 3–5 L is similar to human plasma volume (∼3 L) or blood volume (∼5 L), indicating that the peptide is largely confined to the vascular compartment. This suggests limited distribution into tissues, often due to factors such as high plasma protein binding, large molecular size, or hydrophilicity that restricts extravasation.", "latency_ms": 26603, "timestamp": "2026-02-09T11:52:42.616535+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|OPT-SM-08", "question_id": "OPT-SM-08", "pair_id": "OPT-08", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "In batch Bayesian optimization where you choose 20 compounds per cycle, why is within-batch diversity important, and name one method to enforce it during selection?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Within-batch diversity is crucial in batch Bayesian optimization (with 20 compounds per cycle) to ensure broad exploration of the chemical space, avoid redundant evaluations of similar compounds, and improve the efficiency of the optimization process by maximizing informational gain per cycle. Diversity helps balance exploration and exploitation, leading to more robust surrogate models and faster convergence to optimal compounds.\n\nOne method to enforce within-batch diversity is to use a **greedy selection algorithm with a diversity penalty**, where compounds are selected sequentially by maximizing a score that combines the acquisition function value (e.g., expected improvement) and a penalty based on similarity (e.g., Tanimoto distance) to already chosen compounds in the batch.", "latency_ms": 20893, "timestamp": "2026-02-09T11:53:06.510098+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|SAR-PEP-05", "question_id": "SAR-PEP-05", "pair_id": "SAR-05", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide’s backbone NH at a specific position donates a critical hydrogen bond to the target (distance ~2.9 Å). What is the expected effect on activity of N-methylating that backbone amide at the same position, and what secondary benefit might occur?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "N-methylation removes the hydrogen bond donor, disrupting the critical interaction with the target and leading to a substantial decrease in activity—typically a 10- to 100-fold reduction in binding affinity. A secondary benefit is improved pharmacokinetic properties, such as enhanced metabolic stability (due to resistance to protease cleavage) and increased membrane permeability (by reducing hydrogen bond donor count).", "latency_ms": 14909, "timestamp": "2026-02-09T11:53:24.419526+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ADMET-PEP-06", "question_id": "ADMET-PEP-06", "pair_id": "ADMET-06", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "A 12-mer peptide has net charge +3 and many hydrogen-bond donors (backbone + side chains), giving poor cell permeability. Name two chemical strategies that can increase cell permeability while keeping the same amino-acid sequence identity largely intact, and explain why they work.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Two chemical strategies to increase cell permeability while largely preserving amino-acid sequence identity are:\n\n1. **N-methylation of backbone amides**: Selectively methylating the nitrogen of peptide bonds reduces the number of hydrogen-bond donors. This decreases the peptide's desolvation energy penalty when crossing the lipid bilayer, a major barrier for polar molecules. It can also induce conformational changes that shield polar groups.\n\n2. **Stapling (hydrocarbon stapling)**: Introducing a covalent crosslink (e.g., via olefin metathesis) between side chains stabilizes an α-helical conformation. This reduces the peptide's flexibility and shields backbone polar groups from solvent through intramolecular hydrogen bonding, effectively presenting a more hydrophobic surface.\n\nBoth strategies work by reducing the effective polarity and hydrogen-bonding capacity without altering the side-chain sequence, thereby improving passive diffusion across cell membranes.", "latency_ms": 10443, "timestamp": "2026-02-09T11:53:37.863201+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|GEN-SM-07", "question_id": "GEN-SM-07", "pair_id": "GEN-07", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "Give three commonly used synthesizability/developability filters applied to generated small molecules and provide a typical numeric threshold for at least one of them.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Three commonly used synthesizability/developability filters for generated small molecules are:\n\n1. **Lipinski's Rule of Five**: A developability filter for oral bioavailability, with typical thresholds: molecular weight <500 Da, calculated logP (cLogP) <5, hydrogen bond donors <5, and hydrogen bond acceptors <10.\n2. **Synthetic Accessibility (SA) Score**: A synthesizability metric often calculated using fragment-based methods, where a score <6 (on a scale of 1 to 10, with lower scores indicating easier synthesis) is commonly used as a threshold for prioritization.\n3. **PAINS (Pan-Assay Interference Compounds) Filters**: A set of structural alerts that identify compounds prone to assay interference, applied as a binary filter without a numeric threshold.\n\nFor example, in the Rule of Five, a molecular weight threshold of <500 Da is a typical numeric criterion.", "latency_ms": 17587, "timestamp": "2026-02-09T11:53:58.450828+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ASSAY-SM-04", "question_id": "ASSAY-SM-04", "pair_id": "ASSAY-04", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "A competitive inhibitor has IC50 = 100 nM in an assay run at substrate concentration [S] = 50 µM. The enzyme’s Km for substrate is 10 µM. Using Cheng–Prusoff, estimate Ki.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "The Cheng-Prusoff equation for a competitive inhibitor is:\n\n\\[\nIC_{50} = K_i \\left(1 + \\frac{[S]}{K_m}\\right)\n\\]\n\nRearranging to solve for \\(K_i\\):\n\n\\[\nK_i = \\frac{IC_{50}}{1 + \\frac{[S]}{K_m}}\n\\]\n\nGiven:\n- \\(IC_{50} = 100 \\text{ nM} = 0.1 \\ \\mu\\text{M}\\)\n- \\([S] = 50 \\ \\mu\\text{M}\\)\n- \\(K_m = 10 \\ \\mu\\text{M}\\)\n\nCalculate:\n\n\\[\n\\frac{[S]}{K_m} = \\frac{50}{10} = 5\n\\]\n\\[\n1 + \\frac{[S]}{K_m} = 1 + 5 = 6\n\\]\n\\[\nK_i = \\frac{0.1 \\ \\mu\\text{M}}{6} \\approx 0.0167 \\ \\mu\\text{M} = 16.7 \\text{ nM}\n\\]\n\nThus, the estimated \\(K_i\\) is approximately **17 nM** (rounded to two significant figures).", "latency_ms": 11586, "timestamp": "2026-02-09T11:54:13.037405+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|OPT-SM-07", "question_id": "OPT-SM-07", "pair_id": "OPT-07", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "Adding a fluorine to block a metabolic soft spot increases cLogP from 2.5 to 3.5. What developability risk commonly increases as cLogP rises by ~1 unit, and name one mitigation approach that does not remove the fluorine.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Increasing cLogP by ~1 unit commonly elevates the risk of **poor aqueous solubility", "latency_ms": 19336, "timestamp": "2026-02-09T11:55:18.607165+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ADMET-SM-10", "question_id": "ADMET-SM-10", "pair_id": "ADMET-10", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "What approximate molecular-weight threshold is commonly associated with increased biliary excretion for small molecules, and what other physicochemical features favor biliary vs renal elimination?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "For small molecules, biliary excretion becomes significant at molecular weights **above approximately 500 Da** (often cited as >500-600 Da). This threshold is lower in rats (~325 Da) than in humans.\n\nKey physicochemical features favoring **biliary elimination** over renal elimination include:\n*   **High molecular weight** (>500 Da)\n*   **Amphipathic character** (presence of both polar and non-polar regions)\n*   **Moderate to high lipophilicity** (log P > 0, often >2)\n*   **Presence of polar anionic groups** (e.g., carboxylates, sulfates, glucuronides)\n*   **Substrate affinity for hepatic efflux transporters**, primarily MRP2 (ABCC2) and BCRP (ABCG2), and to a lesser extent P-glycoprotein (MDR1).\n\nIn contrast, **renal elimination** is favored by:\n*   **Low molecular weight** (<500 Da)\n*   **High hydrophilicity** (low log P)\n*   **Permanent positive charge or high polarity** at physiological pH\n*   **Substrate affinity for renal secretory transporters** (e.g., OATs, OCTs).", "latency_ms": 8628, "timestamp": "2026-02-09T11:55:30.236386+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ASSAY-SM-02", "question_id": "ASSAY-SM-02", "pair_id": "ASSAY-02", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "A dose–response curve fit yields a Hill slope of 0.5 (much shallower than 1). Give two mechanistic interpretations relevant to small-molecule assays.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "A Hill slope of 0.5 in a small-molecule dose–response curve suggests a shallower transition than expected for simple one-site binding (nH = 1). Two key mechanistic interpretations are:\n\n1. **Negative cooperativity**: Binding of the small molecule to one site on a multimeric receptor or protein complex reduces the affinity for subsequent molecules, leading to a less steep curve.\n2. **Multiple binding sites or receptor subtypes**: The compound may interact with multiple targets or receptor subtypes with differing affinities, or a single target with multiple independent sites of different affinities, resulting in a composite shallow curve.\n\nThese interpretations are relevant in small-molecule assays for understanding binding kinetics, receptor behavior, and potential polypharmacology.", "latency_ms": 18388, "timestamp": "2026-02-09T11:55:51.625088+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|OPT-SM-05", "question_id": "OPT-SM-05", "pair_id": "OPT-05", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "A lead compound is cleared rapidly due to oxidative N-dealkylation of a tertiary amine. Propose two structural changes that often reduce this clearance while preserving a basic center, and explain why they work.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "", "latency_ms": 26823, "timestamp": "2026-02-09T11:58:36.217838+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "deepseek-v3.2:cloud|GEN-PEP-09", "question_id": "GEN-PEP-09", "pair_id": "GEN-09", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "List four quantitative metrics commonly used to evaluate peptide sequence generative models and briefly state what each measures.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "1. **Diversity**: Measures the variety of generated sequences, typically calculated as the average pairwise distance (e.g., Tanimoto or Levenshtein distance) among generated peptides. High diversity indicates the model explores a broad chemical space.\n\n2. **Novelty**: Assesses how different generated sequences are from the training set, often computed as the average minimum distance between generated peptides and the nearest neighbor in the training data. High novelty indicates generation beyond memorization.\n\n3. **Validity**: The proportion of generated sequences that satisfy biochemical constraints (e.g., correct amino acid alphabet, synthesizable length, or lack of toxic motifs). It measures the model's ability to produce physically plausible peptides.\n\n4. **Property Optimization Success Rate**: The fraction of generated peptides that meet a target property threshold (e.g., antimicrobial activity score > 0.8, or solubility above a cutoff). This evaluates the model's utility for directed design tasks.", "latency_ms": 10462, "timestamp": "2026-02-09T11:58:49.680591+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|OPT-PEP-05", "question_id": "OPT-PEP-05", "pair_id": "OPT-05", "category": "Optimization Approaches", "domain": "peptide", "question_text": "A peptide lead clears rapidly primarily via renal filtration and proteolysis. Name two half-life extension strategies and explain which clearance component each mainly addresses.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "1. **PEGylation** – primarily addresses **renal filtration** by increasing the peptide's hydrodynamic radius above the glomerular filtration cutoff (~30-50 kDa), thereby reducing kidney clearance.\n\n2. **Cyclization** – primarily addresses **proteolysis** by reducing conformational flexibility and shielding cleavage sites, making the peptide less recognizable and accessible to proteolytic enzymes.", "latency_ms": 5628, "timestamp": "2026-02-09T11:58:58.309311+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ASSAY-PEP-01", "question_id": "ASSAY-PEP-01", "pair_id": "ASSAY-01", "category": "Assay Interpretation", "domain": "peptide", "question_text": "Define MIC for an antimicrobial peptide and describe the typical dilution scheme used to measure it (include the standard concentration step size).", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "**MIC (Minimum Inhibitory Concentration)** is the lowest concentration of an antimicrobial peptide (or any antimicrobial agent) that completely inhibits visible growth of a microorganism under defined test conditions.\n\n**Typical Measurement Method: Broth Microdilution**\nThe standard assay follows guidelines from CLSI or EUCAST. A typical dilution scheme is as follows:\n\n1.  **Preparation:** The peptide is serially diluted in a broth medium (e.g., Mueller-Hinton broth) in a 96-well microtiter plate.\n2.  **Standard Concentration Step Size:** Two-fold serial dilutions are used. Each subsequent well contains **half the concentration** of the previous one.\n3.  **Typical Concentration Range:** A common starting concentration is **128 µg/mL**, followed by dilutions:\n    *   **128 → 64 → 32 → 16 → 8 → 4 → 2 → 1 → 0.5 → 0.25 µg/mL**\n    (Some assays may start at 256 µg/mL or higher, depending on the peptide's expected potency).\n4.  **Inoculation:** Each well is inoculated with a standardized bacterial suspension (~5 × 10⁵ CFU/mL).\n5.  **Incubation & Reading:** After incubation (typically 16-20 hours at 35°C), the MIC is read as the **lowest concentration with no visible turbidity**.\n\n**Key Consideration:** For antimicrobial peptides, which can bind to plastic or medium components, the use of polypropylene plates and/or carriers like 0.002% acetic acid with 0.1% BSA is often recommended to prevent loss of peptide and ensure accurate results.", "latency_ms": 10813, "timestamp": "2026-02-09T11:59:12.122842+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ASSAY-SM-10", "question_id": "ASSAY-SM-10", "pair_id": "ASSAY-10", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "An HTS assay has positive-control mean signal μp = 10 with SD σp = 2, and negative-control mean μn = 100 with SD σn = 5. Compute Z' factor and interpret assay quality.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "The Z' factor is calculated as follows:\n\nZ' = 1 - \\frac{3(\\sigma_p + \\sigma_n)}{|\\mu_n - \\mu_p|}  \n= 1 - \\frac{3(2 + 5)}{|100 - 10|}  \n= 1 - \\frac{21}{90}  \n= 1 - 0.2333  \n= 0.7667 (approximately 0.77)\n\nInterpretation: A Z' factor > 0.5 indicates an excellent assay suitable for high-throughput screening. With a value of 0.77, this assay is considered to have excellent quality.", "latency_ms": 8635, "timestamp": "2026-02-09T11:59:23.758916+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|GEN-SM-03", "question_id": "GEN-SM-03", "pair_id": "GEN-03", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "In fragment-based de novo design, why does starting from known fragments often improve hit rates, and what constraint is commonly applied to keep designs synthesizable?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "In fragment-based *de novo* design, starting from known fragments improves hit rates primarily because these fragments are typically small (MW <300), have high ligand efficiency, and represent validated starting points that sample chemical space more efficiently than larger molecules. They often comply with the \"rule of three\" (MW ≤300, cLogP ≤3, H-bond donors/acceptors ≤3), which increases the probability of binding and provides a better starting point for optimization.\n\nTo keep designs synthesizable, a common constraint is the application of **retrosynthetic rules or synthetic accessibility scores** during the *in silico* assembly process. This often involves using known reaction templates or limiting the number of synthetic steps, ensuring that proposed molecules can be feasibly constructed from available building blocks using established chemistry.", "latency_ms": 8719, "timestamp": "2026-02-09T11:59:35.478952+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ASSAY-SM-01", "question_id": "ASSAY-SM-01", "pair_id": "ASSAY-01", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "Define IC50 in a biochemical inhibition assay and state one key assay-condition factor that can shift the measured IC50 without changing true binding affinity.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "IC50 (half-maximal inhibitory concentration) is the concentration of an inhibitor required to reduce the activity of a target enzyme or protein by 50% in a biochemical assay under specified conditions. It serves as a measure of inhibitory potency.\n\nOne key assay-condition factor that can shift the measured IC50 without altering the true binding affinity (Ki) is **substrate concentration**. For example, in competitive inhibition, IC50 = Ki × (1 + [S]/Km), where [S] is substrate concentration and Km is the Michaelis constant. Increasing [S] raises the IC50, even though Ki remains unchanged, due to competition between substrate and inhibitor for the active site.", "latency_ms": 9362, "timestamp": "2026-02-09T11:59:47.841636+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|SAR-PEP-03", "question_id": "SAR-PEP-03", "pair_id": "SAR-03", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A linear 10-mer peptide binds a target in a compact turn-like conformation. What is the most likely effect of head-to-tail cyclization on potency and why (assume cyclization does not directly block a key contact residue)?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Head-to-tail cyclization is likely to increase potency because it reduces the conformational entropy loss upon binding. The linear peptide is flexible and must adopt a compact turn-like conformation when bound; cyclization pre-organizes the peptide into this bioactive conformation, decreasing the entropic penalty and improving binding affinity, assuming no key contacts are obstructed.", "latency_ms": 16130, "timestamp": "2026-02-09T12:00:06.972645+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|SAR-SM-05", "question_id": "SAR-SM-05", "pair_id": "SAR-05", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A ligand’s secondary amide NH donates a hydrogen bond to the target (N–O distance ~2.9 Å) and is critical for potency. What is the expected potency effect of replacing that amide with an ester at the same position, and what other property often changes in parallel?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Replacing the secondary amide with an ester removes the hydrogen bond donor, leading to a significant loss of potency due to the disruption of a critical interaction. In parallel, lipophilicity (log P) typically increases, as esters are generally more lipophilic than amides.", "latency_ms": 18047, "timestamp": "2026-02-09T12:01:45.432780+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|GEN-SM-08", "question_id": "GEN-SM-08", "pair_id": "GEN-08", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "You have a 3D pharmacophore with two H-bond acceptors ~7 Å apart and one hydrophobic feature. How can a generative model be conditioned to satisfy this, and what quantitative post-generation check verifies success?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "To condition a generative model for 3D molecular structures to satisfy a pharmacophore with two H-bond acceptors ~7 Å apart and one hydrophobic feature, the model can be trained or guided using the pharmacophore as a constraint. Common approaches include:\n\n1. **Conditional training**: Represent the pharmacophore as a graph or set of spatial constraints (feature types and distances) and train a model (e.g., a 3D diffusion model or VAE) on molecular data paired with pharmacophore annotations, enabling generation conditioned on this input.\n2. **Guided generation**: During sampling (e.g., in diffusion models), incorporate a guidance signal that penalizes deviations from the target pharmacophore, such as a distance loss between acceptor atoms and a hydrophobic feature loss.\n\nFor **quantitative post-generation verification**:", "latency_ms": 24560, "timestamp": "2026-02-09T12:02:12.993823+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ADMET-SM-05", "question_id": "ADMET-SM-05", "pair_id": "ADMET-05", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "A highly metabolized drug has high intrinsic clearance (CLint >> hepatic blood flow). Using the well-stirred model, how does decreasing the unbound fraction in plasma from fu = 0.01 to fu = 0.005 tend to change hepatic clearance, and why?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "", "latency_ms": 21817, "timestamp": "2026-02-09T12:05:14.942307+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "deepseek-v3.2:cloud|OPT-SM-10", "question_id": "OPT-SM-10", "pair_id": "OPT-10", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "You have four compounds with (IC50 nM, solubility µM, clearance mL/min/kg): A(10, 5, 40), B(30, 50, 20), C(15, 10, 10), D(50, 200, 60). Objectives: minimize IC50 and clearance, maximize solubility. Which compounds are Pareto-optimal?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "", "latency_ms": 19019, "timestamp": "2026-02-09T12:07:43.091640+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "deepseek-v3.2:cloud|GEN-PEP-03", "question_id": "GEN-PEP-03", "pair_id": "GEN-03", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "A peptide binder design strategy fixes a short epitope (e.g., 4 residues) and generates sequences by varying flanking positions. Why can this improve success rates, and what constraint is commonly applied to keep candidates developable?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Fixing a short epitope (e.g., 4 residues) improves success rates by anchoring the peptide to the key binding site on the target, ensuring initial binding affinity while allowing optimization of flanking residues for enhanced specificity, solubility, and stability. This reduces the vast sequence search space, focusing design on variants likely to retain core interactions.\n\nThe common constraint applied to keep candidates developable is **avoiding cysteine residues** (or limiting them) to prevent unwanted disulfide-mediated aggregation, oxidation, and structural complications, thereby improving solubility, stability, and manufacturability. Other constraints may include minimizing methionine (oxidation-prone) or optimizing net charge for solubility.", "latency_ms": 10251, "timestamp": "2026-02-09T12:08:36.723364+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ADMET-PEP-01", "question_id": "ADMET-PEP-01", "pair_id": "ADMET-01", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "What is the typical plasma half-life range for unmodified linear therapeutic peptides, and what are three primary strategies to extend it (include typical timescale changes)?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "The typical plasma half-life of unmodified linear therapeutic peptides is very short, generally ranging from **2 to 30 minutes**. This is due to rapid renal clearance, proteolytic degradation, and sometimes rapid distribution.\n\nThree primary strategies to extend the half-life, with their typical resulting timescales, are:\n\n1.  **PEGylation:** Covalently attaching polyethylene glycol (PEG) chains. This increases hydrodynamic size, reducing renal filtration and shielding from proteases.\n    *   **Timescale change:** Extends half-life from minutes to **hours to several days** (e.g., PEGylated G-CSF has a half-life of ~15-80 hours vs. ~3.5 hours for unmodified).\n\n2.  **Fusion to Long-Lived Carriers:** Genetically fusing the peptide to large plasma proteins with inherently long half-lives, most commonly the **Fc region of an antibody** or **human serum albumin (HSA)**.\n    *   **Timescale change:** Leverages the carrier's half-life (Fc: ~21 days; HSA: ~19 days), extending peptide half-life to the **order of days to weeks**.\n\n3.  **Incorporation of D-Amino Acids or Non-Natural Backbones:** Replacing L-amino acids with their D-enantiomers or using peptidomimetic structures (e.g., peptoids).\n    *   **Timescale change:** This strategy primarily increases metabolic stability against proteases. The extension is more variable but can increase half-life from minutes to **hours**, and in some cases, to over a day when combined with other strategies.", "latency_ms": 10820, "timestamp": "2026-02-09T12:08:50.543785+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ADMET-PEP-05", "question_id": "ADMET-PEP-05", "pair_id": "ADMET-05", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "A peptide’s renal filtration is approximately proportional to its free (unbound) fraction. If lipidation increases albumin binding and reduces fu from 0.5 to 0.01 (50-fold), what qualitative change do you expect in renal clearance and half-life (assume Vd is roughly unchanged)?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Renal clearance decreases proportionally to the reduction in free fraction (approximately 50-fold, from fu = 0.5 to 0.01). With volume of distribution assumed unchanged, half-life increases inversely with the decrease in total clearance; if renal clearance is the dominant elimination pathway, half-life also increases approximately 50-fold.", "latency_ms": 16790, "timestamp": "2026-02-09T12:09:10.335038+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|OPT-SM-04", "question_id": "OPT-SM-04", "pair_id": "OPT-04", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "In Bayesian optimization for molecules, what does Expected Improvement (EI) favor, and why is predictive uncertainty required for principled exploration?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Expected Improvement (EI) in Bayesian optimization for molecules favors candidate molecules where the expected gain over the current best observed property (e.g., binding affinity) is highest. This balances exploitation (selecting molecules with high predicted performance) and exploration (selecting molecules with high predictive uncertainty), as EI is calculated using the full predictive distribution from a probabilistic model like a Gaussian process.\n\nPredictive uncertainty is required for principled exploration because it quantifies the model's confidence in predictions, allowing EI to systematically prioritize under-explored regions of chemical space. Without uncertainty, exploration would be arbitrary or purely exploitative, risking convergence to local optima. The uncertainty term in EI explicitly weights the potential for improvement in uncertain regions, ensuring that exploration is mathematically justified and directed toward areas with high potential for better performance.", "latency_ms": 18453, "timestamp": "2026-02-09T12:09:31.788736+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ASSAY-PEP-02", "question_id": "ASSAY-PEP-02", "pair_id": "ASSAY-02", "category": "Assay Interpretation", "domain": "peptide", "question_text": "A hemolysis assay for an antimicrobial peptide yields a steep dose–response with Hill slope ~3. Give a mechanistic interpretation consistent with peptide membrane-disruption behavior.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "A Hill slope of ~3 indicates strong positive cooperativity, meaning that hemolysis increases sharply over a narrow concentration range. This is consistent with a membrane-disruption mechanism requiring cooperative assembly of multiple peptide molecules—likely three or more—to form pores or aggregates that lyse red blood cells. Such cooperativity is typical of models like toroidal or barrel-stave pore formation, where peptide oligomerization reaches a threshold that triggers rapid membrane disruption.", "latency_ms": 12296, "timestamp": "2026-02-09T12:09:47.085117+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|GEN-SM-09", "question_id": "GEN-SM-09", "pair_id": "GEN-09", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "List four quantitative metrics commonly used to evaluate small-molecule generative models and briefly state what each measures.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "1. **Validity**: Measures the percentage of generated molecules that are chemically feasible (e.g., obeying valency rules), typically reported as a percentage (e.g., >95% for robust models).\n\n2. **Uniqueness**: Assesses the fraction of non-duplicate molecules within a generated set, indicating the model's ability to produce diverse structures rather than repeating outputs (e.g., >80% is often desirable).\n\n3. **Novelty**: Quantifies the proportion of generated molecules not present in the training dataset, usually via structural fingerprint comparisons (e.g., Tanimoto similarity <0.4 to reference compounds).\n\n4. **Drug-likeness**: Evaluates the pharmaceutical relevance of molecules using metrics like Quantitative Estimate of Drug-likeness (QED), which scores compounds from 0 to 1 based on desirable physicochemical properties (e.g., QED >0.6 suggests promising candidates).", "latency_ms": 12313, "timestamp": "2026-02-09T12:10:02.399144+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|GEN-PEP-02", "question_id": "GEN-PEP-02", "pair_id": "GEN-02", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "Protein language models trained with a masked-token objective can be used for peptide ‘inpainting’. What does the masked-token objective learn, and why does it enable filling variable positions around a fixed motif?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "The masked-token objective learns the **conditional probability distribution of amino acids given their surrounding sequence context**. During training, random tokens (e.g., 15% of amino acids) in a protein sequence are replaced with a mask, and the model learns to predict the original identities based on the unmasked context.\n\nThis enables peptide \"inpainting\" with variable positions around a fixed motif because:\n1. **Bidirectional context understanding**: The model processes all unmasked tokens bidirectionally, learning how sequence features (e.g., hydrophobicity, charge, structural constraints) co-vary across positions.\n2. **Conditional generation**: Given a fixed motif (unmasked anchors), the model can fill in masked regions by sampling from the learned distribution of sequences that are compatible with that motif, maintaining biological plausibility.\n3. **Flexible masking patterns**: At inference, any set of positions can be masked, allowing the generation of diverse sequences constrained by the fixed motif, useful for tasks like scaffold design or epitope optimization.\n\nThe model effectively captures co-evolutionary and structural constraints from its training data, allowing it to propose context-appropriate amino acids for masked positions.", "latency_ms": 10228, "timestamp": "2026-02-09T12:10:15.627772+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|GEN-SM-04", "question_id": "GEN-SM-04", "pair_id": "GEN-04", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "What is reaction-aware molecular generation, and why does it typically produce a higher fraction of synthesizable proposals than unconstrained SMILES generation?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Reaction-aware molecular generation is a computational approach in drug discovery that designs new molecules by explicitly incorporating known chemical reaction rules and synthetic pathways during the generation process. Instead of assembling atoms or fragments arbitrarily, it builds molecules through a series of plausible, predefined chemical transformations (e.g., amide coupling, Suzuki reaction).\n\nIt typically produces a higher fraction of synthesizable proposals than unconstrained SMILES generation because:\n\n1.  **Constraint by Real Chemistry**: It uses libraries of validated reaction templates, ensuring that every proposed molecular step or bond formation corresponds to a known laboratory procedure. Unconstrained generation (e.g., via RNNs or VAEs on SMILES strings) often produces chemically invalid or astronomically complex structures that lack a feasible synthetic route.\n\n2.  **Retrosynthetic Logic**: Many methods operate in a retrosynthetic manner, deconstructing target molecules into simpler, available building blocks along known disconnection pathways, thereby guaranteeing a theoretical synthesis plan from the start.\n\n3.  **Focus on Synthetic Accessibility**: The primary objective often includes synthetic accessibility (SA) scores or similar metrics, directly optimizing for ease of synthesis.\n\nAs a result, while unconstrained SMILES generators might yield <10% readily synthesizable molecules, reaction-aware methods can achieve synthesizability rates of **85% to over 95%** for their proposals, as they are inherently biased toward chemically feasible space.", "latency_ms": 16768, "timestamp": "2026-02-09T12:10:46.160538+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|GEN-PEP-01", "question_id": "GEN-PEP-01", "pair_id": "GEN-01", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "In sequence-based peptide generation, what makes a generated peptide sequence syntactically valid, and what additional constraint is often imposed for therapeutic developability?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "In sequence-based peptide generation, a peptide sequence is considered syntactically valid if it consists exclusively of standard amino acid symbols (e.g., the 20 canonical amino acids", "latency_ms": 18871, "timestamp": "2026-02-09T12:11:08.032109+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ASSAY-PEP-08", "question_id": "ASSAY-PEP-08", "pair_id": "ASSAY-08", "category": "Assay Interpretation", "domain": "peptide", "question_text": "In an in vivo antibacterial study, increasing peptide dose increases plasma exposure linearly but bacterial load reduction plateaus at ~60% and does not improve further. What does this suggest mechanistically, and what is one follow-up measurement to confirm?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "The plateau in bacterial load reduction despite linear increases in plasma exposure suggests that the antibacterial effect is limited by factors beyond systemic pharmacokinetics. Possible mechanisms include poor penetration of the peptide into the infection site (e.g., due to tissue barriers or sequestration), saturation of the peptide's mechanism of action (e.g., reaching maximal killing capacity), or the presence of a non-susceptible bacterial subpopulation (e.g., persisters or biofilm-embedded bacteria).\n\nOne key follow-up measurement to confirm limited tissue penetration is to quantify the peptide concentration at the site of infection (e.g., in infected tissues or abscess fluid) across the same dose range. If tissue concentrations", "latency_ms": 21358, "timestamp": "2026-02-09T12:12:02.910772+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|SAR-SM-04", "question_id": "SAR-SM-04", "pair_id": "SAR-04", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A chiral secondary alcohol is positioned so that only the (S)-enantiomer can donate a hydrogen bond to an Asp residue; the (R)-enantiomer points the substituent into a tight hydrophobic cleft causing steric clash. Which enantiomer is expected to be more potent, and what magnitude of potency difference is commonly observed in such cases?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "The (S)-enantiomer is expected to be more potent due to its ability to form a favorable hydrogen bond with the Asp residue, while the (R)-enantiomer suffers from steric clash. In such scenarios, the potency difference typically ranges from 10- to 100-fold (1–2 orders of magnitude), corresponding to a binding energy difference of approximately 1.4–2.7 kcal/mol.", "latency_ms": 13726, "timestamp": "2026-02-09T12:12:19.637443+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ADMET-PEP-10", "question_id": "ADMET-PEP-10", "pair_id": "ADMET-10", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "Why do small peptides (e.g., 1–5 kDa) often clear rapidly via the kidney, and how does increasing hydrodynamic size (e.g., PEGylation) reduce this clearance?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Small peptides (1–5 kDa) clear rapidly via the kidneys primarily due to **glomerular filtration**. The glomerular capillary wall acts as a size- and charge-selective filter:  \n- **Size cutoff**: The effective pore size is ~70–80 Å, allowing free filtration of molecules with a hydrodynamic radius < ~36 Å (corresponding to ~30–50 kDa for globular proteins, but lower for linear peptides).  \n- **Charge selectivity**: The glomerular basement membrane is negatively charged, repelling anionic molecules. Small peptides are often cationic or neutral, facilitating filtration.  \n- **Post-filtration fate**: Filtered peptides are not efficiently reabsorbed in renal tubules (unlike amino acids) and are excreted in urine.\n\n**PEGylation reduces this clearance by increasing hydrodynamic size**:  \n1. **Size exclusion**: Covalent attachment of polyethylene glycol (PEG) increases the peptide’s hydrodynamic radius beyond the glomerular filtration cutoff (>36 Å), even if the peptide itself is small.  \n2. **Charge masking**: PEG shields cationic charges, reducing electrostatic interactions with the negatively charged glomerular filter.  \n3. **Reduced enzymatic degradation**: PEGylation also protects against proteolysis, indirectly reducing clearance by other pathways (e.g., hepatic).\n\n**Example**: A 4 kDa peptide may be filtered rapidly (t₁/₂ ~ minutes), but PEGylation with a 20–40 kDa PEG chain can extend its half-life to hours or days.", "latency_ms": 11568, "timestamp": "2026-02-09T12:12:34.207049+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ADMET-PEP-07", "question_id": "ADMET-PEP-07", "pair_id": "ADMET-07", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "Assume renal plasma flow Qr ≈ 45 L/h. A peptide has renal clearance CLr = 5 L/h. Compute extraction ratio E and state whether clearance is more likely flow-limited or capacity/fu-limited.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "The extraction ratio E is calculated as CLr / Qr = 5 L/h ÷ 45 L/h ≈ 0.11 (or 11%). Given this low extraction ratio, renal clearance is more likely capacity/fu-limited, as elimination depends primarily on intrinsic renal processes (e.g., filtration, secretion) and fraction unbound rather than plasma flow.", "latency_ms": 18774, "timestamp": "2026-02-09T12:12:55.982251+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|OPT-PEP-01", "question_id": "OPT-PEP-01", "pair_id": "OPT-01", "category": "Optimization Approaches", "domain": "peptide", "question_text": "What is an alanine scan in peptide optimization, and what does a large activity loss upon Ala substitution at a position imply about that residue’s role?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "An alanine scan is a systematic mutagenesis technique used in peptide optimization where each amino acid residue in a peptide sequence is replaced, one at a time, with alanine. The purpose is to assess the functional contribution of each side chain. Alanine is chosen because its side chain (a methyl group) is small, non-reactive, and non-chiral; it essentially removes the original side chain's chemical functionality beyond the beta-carbon while maintaining the peptide's backbone structure.\n\nA large loss of biological activity upon substitution with alanine implies that the side chain of the original residue is **critical for the peptide's function**. This typically indicates the residue is involved in:\n\n1.  **Direct interaction** with the target (e.g., forming a hydrogen bond, ionic interaction, or hydrophobic contact in the binding pocket).\n2.  **Maintaining a specific local structure** (e.g., a proline that induces a turn, or a residue critical for forming an alpha-helix or beta-sheet).\n3.  **A conformational change** necessary for activity.\n\nSuch a residue is often termed a \"hot spot\" and is usually considered essential to retain or optimize further in drug design. Conversely, positions where alanine substitution causes little or no activity loss are considered tolerant, suggesting their side chains are not directly involved in function, and they may be modified to improve other properties (e.g., stability, solubility).\n\n**Important nuance:** A large activity loss does not *necessarily* mean the residue makes a direct contact; it could also be critical for maintaining the overall peptide fold. Further structural studies (e.g., NMR, crystallography) are typically needed to distinguish between direct binding and structural roles.", "latency_ms": 16414, "timestamp": "2026-02-09T12:13:15.397103+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|SAR-PEP-09", "question_id": "SAR-PEP-09", "pair_id": "SAR-09", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide’s Lys side chain forms a salt bridge to an Asp on the target protein (N–O distance ~2.8 Å). You mutate Lys to Gln at that position. What is the most likely effect on binding/activity and why?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "The mutation from Lys to Gln is likely to decrease binding affinity and activity. This is because the salt bridge between the positively charged Lys side chain and the negatively charged Asp side chain is a strong electrostatic interaction, typically contributing 3–5 kcal/mol to binding energy. The short distance (~2.8 Å) indicates a particularly favorable interaction. Gln, while polar and capable of hydrogen bonding, lacks a formal positive charge and cannot fully compensate for the loss of this salt bridge, leading to weaker binding.", "latency_ms": 15897, "timestamp": "2026-02-09T12:14:08.220218+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ASSAY-SM-09", "question_id": "ASSAY-SM-09", "pair_id": "ASSAY-09", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "A PK/PD plot of effect vs plasma concentration shows counterclockwise hysteresis (effect lags concentration early and increases later at the same concentration). What does this imply about system dynamics, and what sampling strategy improves model identifiability?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Counterclockwise hysteresis in a PK/PD plot (effect vs. plasma concentration) implies that the observed pharmacological effect lags behind the plasma concentration of the administered drug. This is characteristic of systems with a **delayed response**, most commonly due to one of two dynamics:\n\n1.  **Indirect Response Models:** The drug acts by inhibiting the production or stimulating the loss of a mediator, which then causes the observed effect. The time course of the mediator creates the hysteresis loop.\n2.  **Formation of an Active Metabolite:** The measured parent drug concentration declines, but its active metabolite (which may not be measured) forms later, leading to a persistent or increasing effect.\n\nTo improve model identifiability for such systems, the sampling strategy must adequately characterize the **temporal disconnect** between concentration and effect:\n\n*   **Sample intensively during both the rising and falling phases** of the plasma concentration curve.\n*   **Crucially, extend sampling well into the post-distribution phase** to capture the full dissipation of the effect. This is often where the hysteresis loop closes.\n*   A **prolonged sampling period** is more important than very frequent early sampling alone, as it allows observation of the effect at low concentrations when the hysteresis is most apparent.\n\nIn summary, this hysteresis indicates a system where effect is not a direct, instantaneous function of plasma concentration. Identifiability is improved by a sampling strategy that captures the complete time course of both concentration and effect, especially during the effect's delayed decline.", "latency_ms": 15648, "timestamp": "2026-02-09T12:14:26.868664+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|SAR-SM-06", "question_id": "SAR-SM-06", "pair_id": "SAR-06", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A kinase inhibitor relies on a heteroaromatic ring to form two hinge hydrogen bonds (one acceptor and one donor). What is the most likely potency effect of replacing that heteroaromatic ring with a phenyl ring at the same position, and why?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Replacing the heteroaromatic ring with a phenyl ring will likely decrease potency significantly because the phenyl ring lacks hydrogen bond donor and acceptor atoms. This eliminates the two critical hydrogen bonds with the kinase hinge region, which are essential for binding affinity and often contribute to sub-micromolar potency. For example, such a change could lead to a 10- to 100-fold or greater increase in IC₅₀, depending on the specific inhibitor and kinase.", "latency_ms": 8947, "timestamp": "2026-02-09T12:14:38.816948+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|GEN-PEP-07", "question_id": "GEN-PEP-07", "pair_id": "GEN-07", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "Give three developability/manufacturability filters applied to generated peptide sequences and provide a typical numeric threshold for at least one (e.g., charge or length).", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Three common developability/manufacturability filters for peptide sequences are:\n\n1. **Peptide Length** – Long sequences complicate synthesis and reduce yield. A typical threshold is ≤40 amino acids to ensure efficient solid-phase peptide synthesis and acceptable purity.\n2. **Net Charge at Physiological pH** – Extreme charges can impair solubility and increase non-specific binding. Sequences are often filtered to maintain a net charge between –3 and +3 at pH 7.4.\n3. **Hydrophobicity** – High hydrophobicity promotes aggregation and poor solubility. Peptides with a Grand Average of Hydropathy (GRAVY) score >0.5 are frequently excluded.\n\nFor example, the net charge filter typically uses a threshold range of –3 to +3.", "latency_ms": 17073, "timestamp": "2026-02-09T12:14:58.890797+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ASSAY-SM-06", "question_id": "ASSAY-SM-06", "pair_id": "ASSAY-06", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "A compound has target IC50 = 200 nM and cellular CC50 (viability) = 20 µM. Compute the in vitro safety window (CC50/IC50) and state one follow-up assay you would run to contextualize the cytotoxicity.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "The in vitro safety window (CC50/IC50) is 100. One follow-up assay to contextualize the cytotoxicity would be to test the compound in cells lacking the target (e.g., using genetic knockout or knockdown) to determine if the cytotoxicity is target-mediated or due to off-target effects.", "latency_ms": 13705, "timestamp": "2026-02-09T12:15:15.596530+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|SAR-PEP-06", "question_id": "SAR-PEP-06", "pair_id": "SAR-06", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A stapled α-helical peptide binds a protein–protein interaction target, and CD measurements show ~60% helicity in solution. What is the most likely activity effect of removing the staple (keeping the same sequence otherwise), and why?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Removing the staple is most likely to decrease the peptide's binding activity. The staple stabilizes the α-helical conformation, as shown by the 60% helicity in solution. Without it, the peptide will have reduced helical content, increasing the entropic penalty for adopting the bioactive conformation upon binding and decreasing the population of the active conformation, leading to weaker target interaction.", "latency_ms": 18754, "timestamp": "2026-02-09T12:15:37.350900+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|OPT-SM-01", "question_id": "OPT-SM-01", "pair_id": "OPT-01", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "What is matched molecular pair (MMP) analysis, and how is it used to prioritize substitutions during lead optimization?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Matched molecular pair (MMP) analysis is a computational method used in medicinal chemistry to systematically identify and analyze the effects of small, well-defined structural changes on molecular properties, most notably biological activity.\n\nAn MMP is defined as a pair of molecules that differ only by a single, localized structural transformation (e.g., -Cl → -OCH₃, or -H → -cyclopropyl). The core scaffold remains identical.\n\n### How MMP Analysis Works:\n1.  **Identification:** A large dataset of compounds with associated property data (e.g., IC₅₀, solubility, logP) is mined to find all possible matched pairs.\n2.  **Quantification:** For a given transformation (e.g., -Cl → -CF₃), the median change in the property of interest (ΔProperty) is calculated across all instances found in the dataset.\n3.  **Statistical Context:** The analysis provides the frequency of the transformation and the variance of its effect (e.g., standard deviation or interquartile range), indicating how consistent and reliable the change is.\n\n### Use in Prioritizing Substitutions During Lead Optimization:\nMMP analysis is used as a **data-driven guide** to prioritize chemical substitutions by predicting their likely impact. It helps answer: \"If I replace this group with another, what typically happens to potency or solubility?\"\n\n1.  **Prioritizing R-groups for Potency:** If a lead compound has a -Cl substituent, an MMP database can show that, historically, the transformation -Cl → -CF₃ has a median **+0.5 log unit increase in potency** (a ~3x improvement) across similar chemotypes. This makes -CF₃ a high-priority substitution to test. Conversely, -Cl → -CH₃ might show a neutral or negative median effect, deprioritizing it.\n\n2.  **Avoiding Detrimental Changes:** It can flag transformations that consistently degrade a key property. For example, a particular aromatic substitution might show a strong correlation with decreased solubility, steering chemists away from that option.\n\n3.  **Identifying Multiproperty Optimizations:** It can highlight transformations that favorably impact multiple properties simultaneously (e.g., a -CN group that typically increases potency *and* improves metabolic stability).\n\n4.  **Context-Aware Guidance:** Advanced MMP analyses consider the local chemical environment (context), recognizing that the effect of -Cl → -OCH₃ may differ if it's on a phenyl ring versus a pyridine. This allows for more precise, scaffold-specific prioritization.\n\n**In summary, MMP analysis transforms historical project data and large-scale corporate databases into actionable, statistical trends. It prioritizes substitutions by predicting their probable quantitative effect on key properties, reducing reliance on intuition alone and helping focus synthetic efforts on the most promising chemical modifications.** It is typically used alongside other methods (e.g., QSAR, free-energy calculations) as part of an integrated lead optimization strategy.", "latency_ms": 19408, "timestamp": "2026-02-09T12:15:59.759998+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ADMET-PEP-09", "question_id": "ADMET-PEP-09", "pair_id": "ADMET-09", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "In an in vivo PK study, a peptide shows accelerating clearance over repeated weekly dosing despite similar initial exposure. What two mechanisms can cause this, and what measurements distinguish them?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Two primary mechanisms can cause accelerating clearance of a peptide with repeated weekly dosing:\n\n1.  **Immunogenicity (Anti-Drug Antibody Formation):** Repeated dosing can induce an immune response, generating anti-drug antibodies (ADAs). These antibodies can bind to the peptide, forming complexes that are rapidly cleared from circulation via the reticuloendothelial system (RES).\n2.  **Target-Mediated Drug Disposition (TMDD) with Upregulation:** The peptide may bind to a specific, saturable biological target (e.g., a receptor). With chronic weekly dosing, the target expression can be upregulated, increasing the capacity for binding and subsequent internalization and degradation of the peptide.\n\n**Distinguishing Measurements:**\n\n*   To identify **Immunogenicity**, measure **anti-drug antibody (ADA) titers and neutralizing capacity** in serum samples collected pre-dose and post-dose. A correlation between rising ADA titers and increasing clearance is diagnostic.\n*   To identify **TMDD with upregulation**, assess **target expression levels** (e.g., via mRNA or flow cytometry) in relevant tissues or measure **receptor occupancy kinetics**. Evidence of increased target expression or accelerated post-dose receptor occupancy over the dosing period supports this mechanism.\n\n**Note:** The two mechanisms can coexist. The similar initial exposure (e.g., Cmax or AUC after the first dose) rules out simple changes in absorption or distribution, focusing the cause on clearance pathways that intensify with time.", "latency_ms": 15149, "timestamp": "2026-02-09T12:16:17.910073+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|SAR-PEP-02", "question_id": "SAR-PEP-02", "pair_id": "SAR-02", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide’s Asp side chain forms a salt bridge to a Lys on the target protein (distance ~2.8–3.0 Å) and is required for activity. What is the most likely effect on potency if Asp is substituted with Asn at that position, and why?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Substituting Asp with Asn will most likely cause a substantial decrease in potency (e.g., a 10- to 1000-fold increase in IC₅₀) because the negatively charged carboxylate side chain of Asp, which forms a critical salt bridge with the Lys side chain of the target protein, is replaced by a neutral carboxamide. This eliminates the strong electrostatic interaction (typically contributing ~3–5 kcal/mol to binding energy) that is essential for activity. Although Asn may form hydrogen bonds, these are weaker and unlikely to compensate for the loss of the salt bridge, especially at the optimal distance of 2.8–3.0 Å for ionic pairing.", "latency_ms": 17482, "timestamp": "2026-02-09T12:17:10.409106+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ASSAY-PEP-10", "question_id": "ASSAY-PEP-10", "pair_id": "ASSAY-10", "category": "Assay Interpretation", "domain": "peptide", "question_text": "A peptide screening assay has positive-control mean μp = 20 with SD σp = 3, and negative-control mean μn = 100 with SD σn = 6. Compute Z' factor and interpret assay quality.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "The Z' factor is calculated as follows:\n\nZ' = 1 - (3 × (σp + σn)) / |μn - μp|  \n= 1 - (3 × (3 + 6)) / |100 - 20|  \n= 1 - (3 × 9) / 80  \n= 1 - 27 / 80  \n= 1 - 0.3375  \n= 0.6625\n\nInterpretation: A Z' factor > 0.5 indicates an excellent assay with sufficient separation between positive and negative controls, making it suitable for high-throughput screening.", "latency_ms": 11474, "timestamp": "2026-02-09T12:17:24.883958+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ADMET-SM-03", "question_id": "ADMET-SM-03", "pair_id": "ADMET-03", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "What physicochemical profile is commonly associated with hERG liability, and what in vitro hERG IC50 threshold is often treated as a significant flag for follow-up?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Compounds with hERG potassium channel blockade liability (associated with QT prolongation and Torsades de Pointes) commonly share a specific physicochemical profile:\n\n*   **High lipophilicity** (typically cLogP > 3)\n*   **Basic pKa** (often a tertiary amine with pKa > 8)\n*   **Aromatic/heteroaromatic rings** that can engage in π-stacking interactions within the channel's hydrophobic cavity.\n\nFor **in vitro hERG IC₅₀**, a value **< 1 µM** is widely treated as a significant flag mandating follow-up electrophysiology studies (e.g., patch-clamp) and integrated risk assessment. Many discovery projects use a more conservative **threshold of 10 µM** in primary screening to deprioritize compounds with even moderate potential for hERG inhibition.", "latency_ms": 9702, "timestamp": "2026-02-09T12:17:37.586481+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ADMET-PEP-02", "question_id": "ADMET-PEP-02", "pair_id": "ADMET-02", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "A linear peptide is rapidly cleaved by trypsin-like proteases at a Lys site (cleavage after Lys). Name two peptide modifications that typically reduce this cleavage and explain why serum stability increases (include a typical qualitative timescale change).", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Two modifications that reduce trypsin cleavage at a Lys site are:\n\n1. **Acetylation of the Lysine side chain (ε-amino group)**:  \n   This converts the positively charged primary amine (NH₃⁺) to a neutral acetamide (NHCOCH₃). Trypsin recognizes and cleaves after basic residues (Lys, Arg) primarily through electrostatic interaction with the substrate's positive charge. Acetylation eliminates this charge and introduces steric bulk, severely impairing protease binding and catalysis.\n\n2. **Substitution with D-amino acids at the cleavage site (e.g., D-Lys or D-Arg at the P1 position, or D-amino acids at adjacent positions)**:  \n   Trypsin-like proteases are stereospecific for L-amino acids. Incorporating a D-amino acid at the cleavage site (or nearby) disrupts the optimal geometry required for the substrate to fit into the enzyme's active site, preventing efficient hydrolysis.\n\n**Typical qualitative timescale change**:  \nUnmodified linear peptides with a Lys cleavage site are often degraded in serum within **minutes to a few hours**. With these modifications, serum stability can increase to **several hours to days**, representing a shift from rapid clearance to sustained exposure.", "latency_ms": 11254, "timestamp": "2026-02-09T12:18:23.594298+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ADMET-SM-08", "question_id": "ADMET-SM-08", "pair_id": "ADMET-08", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "A basic drug has pKa = 9.5 and cLogP = 3.5. At intestinal pH 6.5, approximately what fraction is un-ionized, and what does that imply for passive permeability?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "At intestinal pH 6.5, approximately 0.1% (1/1000) of the drug is un-ionized, calculated using the Henderson-Hasselbalch equation for a base (f_un-ionized = 1/(1+10^(pKa-pH))).\n\nDespite the high lipophilicity (cLogP = 3.5), passive permeability is expected to be low because the ionized form predominates and neutral species diffuse more readily across lipid membranes.", "latency_ms": 28581, "timestamp": "2026-02-09T12:19:24.001888+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|OPT-SM-03", "question_id": "OPT-SM-03", "pair_id": "OPT-03", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "In a QSAR-guided lead-optimization loop, what minimum experimental data characteristics are needed to retrain reliably and reduce overfitting risk?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "For reliable retraining in a QSAR-guided lead-optimization loop and to minimize overfitting, the minimum experimental data should meet these key characteristics:\n\n1.  **Sample Size:** A minimum of **30-50 well-measured, unique compounds** is essential. This provides a baseline for model stability. For more complex models (e.g., non-linear machine learning), **>100 compounds** are strongly recommended.\n\n2.  **Activity Range and Distribution:** The biological activity (e.g., pIC₅₀) should span **at least 2-3 logarithmic units (a 100 to 1000-fold concentration range)**. The data should be relatively evenly distributed across this range, not heavily clustered.\n\n3.  **Structural Diversity:** The dataset must contain **meaningful structural variation** relevant to the optimization campaign. This includes diverse substituents and core modifications (scaffold hopping) to ensure the model learns structure-activity relationships, not just noise.\n\n4.  **Assay Quality:** Data must come from a **consistent, robust, and reproducible biological assay** (preferably within the same experimental batch for the training set) to minimize noise that the model might overfit.\n\n5.  **Validation Protocol:** The retraining process itself must use **rigorous validation**, such as:\n    *   A **dedicated, external test set** (minimum 15-20% of the data, not used in training).\n    *   **Cross-validation** (e.g., 5-fold) with careful **y-scrambling** to confirm the model is not fitting to chance correlations.\n\n**In summary:** The reliable minimum is **~50 diverse compounds with accurately measured activities spanning >2 log units**, coupled with strict validation practices. Using fewer compounds or a narrow activity range significantly increases overfitting risk, leading to poor predictive performance for new analogs.", "latency_ms": 14645, "timestamp": "2026-02-09T12:19:41.647792+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|GEN-PEP-05", "question_id": "GEN-PEP-05", "pair_id": "GEN-05", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "You condition a peptide generator to maximize predicted activity from an in silico model. What is a common failure mode, and what validation step reduces the risk of selecting ‘adversarial’ sequences?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "A common failure mode is generating peptides that exploit biases or artifacts in the *in silico* model's training data or architecture, rather than learning the true structure-activity relationship. These \"adversarial\" sequences achieve high predicted scores but lack real-world biological activity.\n\nThe critical validation step is **orthogonal experimental testing** using a functional assay distinct from the data used to train the model. For example, if the model was trained on *in vitro* binding data, validation should involve a cell-based activity assay or *in vivo* testing. This step directly measures the actual biological function, filtering out sequences that only \"hack\" the predictive model.", "latency_ms": 9020, "timestamp": "2026-02-09T12:19:53.668343+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|SAR-SM-09", "question_id": "SAR-SM-09", "pair_id": "SAR-09", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A tertiary amine (pKa ~9) forms a salt bridge to an Asp in the binding site (N–O distance ~2.8 Å). You replace the tertiary amine with an amide at the same position. What is the most likely potency effect and why?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Replacing the tertiary amine with an amide will likely decrease potency. The tertiary amine (pKa ~9) is protonated and positively charged at physiological pH, forming a strong salt bridge with the negatively charged Asp. The amide, however, is neutral at physiological pH (pKa ~0 to -1) and cannot participate in an ionic interaction. Although the amide may form a hydrogen bond with Asp, this interaction is typically weaker (∼1–3 kcal/mol) than a salt bridge (∼3–5 kcal/mol), leading to a net loss in binding affinity.", "latency_ms": 21466, "timestamp": "2026-02-09T12:22:42.239324+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ASSAY-SM-05", "question_id": "ASSAY-SM-05", "pair_id": "ASSAY-05", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "A compound’s apparent IC50 shifts from 1.0 µM with 5-minute preincubation to 50 nM with 60-minute preincubation. What mechanism does this suggest, and what follow-up assay distinguishes covalent from slow-tight binding?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "The shift in IC50 from 1.0 µM (5-minute preincubation) to 50 nM (60-minute preincubation) indicates time-dependent inhibition, which is characteristic of either a covalent (irreversible) inhibitor or a slow-tight binding (reversible) inhibitor.\n\nTo distinguish between these mechanisms, a **dilution assay** (e.g., jump-dilution) is commonly used. After preincubating the enzyme with the inhibitor, the mixture is diluted significantly (e.g., 100-fold) into a substrate-containing buffer. For a covalent inhibitor, enzyme activity remains suppressed due to irreversible modification, while for a slow-tight binding inhibitor, activity", "latency_ms": 19187, "timestamp": "2026-02-09T12:23:04.426796+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ASSAY-PEP-07", "question_id": "ASSAY-PEP-07", "pair_id": "ASSAY-07", "category": "Assay Interpretation", "domain": "peptide", "question_text": "Three peptide variants have (EC50 nM, serum stability t1/2 min): A(30, 15), B(80, 240), C(20, 5). If you require EC50 ≤ 50 nM and serum t1/2 ≥ 60 min for the next round, which variant best meets criteria and what is the most logical next step?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "", "latency_ms": 19863, "timestamp": "2026-02-09T12:26:05.103837+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "deepseek-v3.2:cloud|ADMET-SM-01", "question_id": "ADMET-SM-01", "pair_id": "ADMET-01", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "State Lipinski’s Rule-of-Five thresholds (MW, cLogP, HBD, HBA) and give two mechanistic reasons why violating multiple thresholds tends to reduce oral exposure.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Lipinski's Rule-of-Five thresholds are:\n- Molecular weight (MW) ≤ 500 Daltons\n- Calculated LogP (cLogP) ≤ 5\n- Hydrogen bond donors (HBD) ≤ 5\n- Hydrogen bond acceptors (HBA) ≤ 10\n\nViolating multiple thresholds tends to reduce oral exposure due to two key mechanistic reasons:\n1. **Poor aqueous solubility and dissolution**: High MW and high cLogP often lead to low solubility in gastrointestinal fluids, limiting dissolution—a critical step for passive absorption. For example, compounds with MW >500 and cLogP >5 may precipitate or have insufficient dissolved drug for absorption.\n2. **Reduced passive permeability across intestinal membranes**: High MW and excessive hydrogen bonding (HBD >5, HBA >10) hinder diffusion through lipid bilayers. Larger molecules struggle to traverse membranes, and increased polarity from hydrogen bonds raises the desolvation energy barrier, impairing partitioning into lipophilic epithelial cells.", "latency_ms": 20942, "timestamp": "2026-02-09T12:26:29.046285+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ASSAY-PEP-06", "question_id": "ASSAY-PEP-06", "pair_id": "ASSAY-06", "category": "Assay Interpretation", "domain": "peptide", "question_text": "An antimicrobial peptide has MIC = 5 µg/mL and hemolysis HC50 = 25 µg/mL. Compute TI (HC50/MIC) and state why this is a concern and one design direction to reduce hemolysis.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "The therapeutic index (TI) is calculated as HC50/MIC = 25 µg/mL / 5 µg/mL = 5. This low TI indicates a narrow therapeutic window, meaning the peptide may cause significant hemolysis at concentrations only slightly above the antimicrobial effective dose, posing a safety risk for therapeutic use.\n\nOne design direction to reduce hemolysis is to modify the peptide's structure to enhance selectivity for microbial membranes over host cell membranes. For example, reducing overall hydrophobicity or increasing cationic residues can improve targeting of negatively charged microbial membranes while minimizing interaction with neutral mammalian membranes.", "latency_ms": 9842, "timestamp": "2026-02-09T12:26:41.888659+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|SAR-PEP-10", "question_id": "SAR-PEP-10", "pair_id": "SAR-10", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide bond adjacent to a Pro residue exists as a cis/trans mixture in solution, but only the trans conformer binds the target. What modification is most likely to increase apparent potency, and why?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "", "latency_ms": 21998, "timestamp": "2026-02-09T12:29:21.471408+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "deepseek-v3.2:cloud|GEN-SM-05", "question_id": "GEN-SM-05", "pair_id": "GEN-05", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "You condition a generator to maximize a QSAR-predicted property (e.g., potency) using classifier guidance. What is a common failure mode of this approach, and what is one practical way to detect it?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "A common failure mode is that the generator exploits the QSAR model's limitations, producing molecules with high predicted potency but poor real-world validity (e.g., unrealistic structures or adversarial examples). One practical way to detect this is to evaluate the generated molecules with an independent QSAR model or ensemble and flag those with large prediction discrepancies.", "latency_ms": 9071, "timestamp": "2026-02-09T12:29:33.543520+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|SAR-PEP-08", "question_id": "SAR-PEP-08", "pair_id": "SAR-08", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide binds as an α-helix but is mostly disordered in solution. Stapling increases preorganization and improves binding free energy by ~1.0 kcal/mol. Approximately what fold-improvement in affinity would you expect at 298 K, and what is the mechanism?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "A 1.0 kcal/mol improvement in binding free energy at 298 K corresponds to approximately a 5- to 6-fold increase in affinity (specifically ~5.4-fold, calculated using ΔΔG = –RT ln(K₂/K₁), with RT ≈ 0.592 kcal/mol). The mechanism is primarily entropic: stapling preorganizes the peptide into the active α-helical conformation, reducing the conformational entropy loss that would otherwise occur upon binding from a disordered state in solution.", "latency_ms": 16130, "timestamp": "2026-02-09T12:29:52.674773+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|SAR-PEP-07", "question_id": "SAR-PEP-07", "pair_id": "SAR-07", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide binds both a target protein and a close homolog. Only the target has a Tyr OH positioned to hydrogen-bond with a side-chain acceptor at the interface. What is the expected effect on potency and selectivity of substituting a Val at the interface to an Asn (introducing a side-chain carbonyl acceptor), and why?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Substituting Val with Asn introduces a side-chain carbonyl acceptor that can form a hydrogen bond with the Tyr OH in the target protein. This interaction is absent in the homolog, which lacks the Tyr OH. Therefore, potency for the target increases due to the additional favorable interaction, while potency for the homolog likely decreases or remains unchanged due to desolvation costs without compensation. Overall, selectivity for the target over the homolog increases.", "latency_ms": 13043, "timestamp": "2026-02-09T12:30:08.718892+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|SAR-PEP-04", "question_id": "SAR-PEP-04", "pair_id": "SAR-04", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide binds its target as an α-helix, and residue i is buried in a helix-dependent interface. What is the most likely effect on activity of substituting that residue from an L-amino acid to the corresponding D-amino acid, and why?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Substituting an L-amino acid with its D-enantiomer at a buried, helix-dependent interface will most likely abolish or severely reduce activity. This is because D-amino acids are incompatible with the right-handed α-helical conformation adopted by L-peptides: the substitution disrupts backbone dihedral angles, destabilizing the helix and altering side-chain orientation. Since binding depends on both the helical structure and proper burial of residue i, these disruptions prevent effective interaction with the target.", "latency_ms": 18882, "timestamp": "2026-02-09T12:30:41.409133+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ADMET-SM-02", "question_id": "ADMET-SM-02", "pair_id": "ADMET-02", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "A benzylic CH2 is identified as the major CYP oxidation soft spot (rapid benzylic hydroxylation). Name one structural change that typically reduces this metabolism and explain the mechanism (include a typical magnitude of intrinsic clearance reduction).", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Deuterium substitution at the benzylic position is a common structural change to reduce CYP-mediated benzylic hydroxylation. This approach leverages the kinetic isotope effect: the carbon-deuterium bond is stronger than the carbon-hydrogen bond due to lower zero-point energy, increasing the activation energy for hydrogen atom abstraction by CYP enzymes. As a result, the rate of hydroxylation is slowed. Typically, this reduces the intrinsic clearance for that specific metabolic pathway by 2- to 10-fold, depending on the compound and enzyme involved.", "latency_ms": 14522, "timestamp": "2026-02-09T12:30:58.932318+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|GEN-SM-06", "question_id": "GEN-SM-06", "pair_id": "GEN-06", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "Name two generation-time techniques that increase diversity of generated small molecules and one quantitative metric commonly used to measure diversity in molecular sets.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Two generation-time techniques that enhance diversity in small molecule generation are:\n\n1. **High-temperature sampling in probabilistic models**: Increasing the temperature parameter during sampling from models like variational autoencoders (VAEs) or recurrent neural networks (RNNs) flattens the output probability distribution, promoting exploration of less likely but more diverse molecular structures.\n2. **Diversity-promoting loss functions**: Incorporating explicit diversity penalties or objectives during training, such as maximizing entropy or minimizing pairwise similarities in generated batches, encourages the model to produce a broader range of molecules.\n\nOne quantitative metric commonly used to measure diversity in molecular sets is the **average pairwise Tanimoto distance** based on molecular fingerprints (e.g., Morgan fingerprints). This metric calculates the complement of average pairwise Tanimoto similarity, providing a value where higher scores indicate greater diversity.", "latency_ms": 23664, "timestamp": "2026-02-09T12:32:06.916887+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ASSAY-SM-03", "question_id": "ASSAY-SM-03", "pair_id": "ASSAY-03", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "A compound has IC50 = 50 nM on the intended target and IC50 = 5 µM on an off-target. Compute the selectivity ratio and interpret whether this is generally considered strong selectivity.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "The selectivity ratio is 100-fold (IC50 off-target/IC50 on-target = 5 µM / 50 nM = 100). This is generally considered moderate to good selectivity in drug discovery, as it indicates a clear preference for the intended target. However, the adequacy of this selectivity depends on the specific therapeutic context; for some targets, higher selectivity (e.g., >1000-fold) may be required to minimize off-target effects and ensure safety.", "latency_ms": 17103, "timestamp": "2026-02-09T12:32:27.020822+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|OPT-SM-06", "question_id": "OPT-SM-06", "pair_id": "OPT-06", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "A small molecule inhibits both the intended kinase and a close off-target kinase. Structural data indicate the intended target has a larger lipophilic pocket extension that the off-target lacks. What modification strategy is most likely to improve selectivity, and why?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "To improve selectivity for the intended kinase, add a lipophilic substituent to the inhibitor that extends into the larger lipophilic pocket unique to the target. This modification increases binding affinity for the intended kinase through favorable van der Waals interactions within the extra space, while simultaneously creating steric clash or poor hydrophobic contact in the off-target kinase's more constrained pocket, thereby reducing its binding. This strategy directly exploits the structural difference to achieve selectivity.", "latency_ms": 6687, "timestamp": "2026-02-09T12:32:36.708934+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|OPT-PEP-10", "question_id": "OPT-PEP-10", "pair_id": "OPT-10", "category": "Optimization Approaches", "domain": "peptide", "question_text": "You have four peptides with (EC50 nM, serum half-life h, hemolysis HC50 µg/mL): A(10, 0.2, 50), B(30, 8, 40), C(15, 2, 200), D(50, 20, 20). Objectives: minimize EC50, maximize half-life, maximize HC50. Which peptides are Pareto-optimal?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "", "latency_ms": 18308, "timestamp": "2026-02-09T12:35:07.216607+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "deepseek-v3.2:cloud|ASSAY-SM-08", "question_id": "ASSAY-SM-08", "pair_id": "ASSAY-08", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "A compound tested as a receptor agonist reaches only 60% of the maximal response produced by a known full agonist, even at saturating concentrations. What does this imply about the compound’s pharmacology, and how should EC50 be interpreted?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "The compound is a **partial agonist**, as it produces a submaximal response (60% of the maximal response of a full agonist) even at receptor-saturating concentrations. This indicates it has **lower intrinsic efficacy** compared to the full agonist.\n\nThe **EC₅₀** for this compound is the concentration that produces 50% of its own maximal response (i.e.,", "latency_ms": 23138, "timestamp": "2026-02-09T12:35:33.355894+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|OPT-PEP-07", "question_id": "OPT-PEP-07", "pair_id": "OPT-07", "category": "Optimization Approaches", "domain": "peptide", "question_text": "Cyclization improves a peptide’s protease stability but reduces affinity because the ring distorts the bioactive geometry. What optimization lever can restore affinity while keeping most of the stability gain, and why?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "The primary optimization lever is **systematic variation of the cyclization linker (e.g., length, composition, and stereochemistry)**. By screening a library of cyclic peptides with different linkers, one can identify a variant where the ring constraint *accidentally* or *designedly* better pre-organizes the pharmacophores into the bioactive conformation for the target, thereby restoring affinity while maintaining the proteolytic stability conferred by cyclization. This works because the linker directly defines the macrocycle's conformation; altering it can reposition critical side chains without reintroducing backbone flexibility that leads to rapid cleavage.", "latency_ms": 11324, "timestamp": "2026-02-09T12:35:47.680501+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|GEN-PEP-08", "question_id": "GEN-PEP-08", "pair_id": "GEN-08", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "In structure-conditioned peptide design for a binding groove, what is typically held fixed vs optimized (backbone vs side chains), and what quantitative structural metric can verify that the designed peptide matches the intended fold?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "In structure-conditioned peptide design for a binding groove:\n\n**Typically held fixed:**\n*   The **backbone conformation** (φ/ψ angles) of the peptide's core binding motif is held fixed to match the complementary shape of the target groove. Limited backbone flexibility may be allowed in terminal or loop regions not directly involved in binding.\n\n**Typically optimized:**\n*   The **side-chain identities and rotamers** are optimized to maximize binding affinity and specificity. This includes selecting amino acids and their conformations to form favorable interactions (e.g., hydrogen bonds, salt bridges, van der Waals contacts) with the groove.\n\n**Key quantitative structural metric for verification:**\n*   **Backbone Root-Mean-Square Deviation (RMSD)** between the designed peptide and the intended/target fold (typically the starting scaffold conformation). A successful design closely maintains the intended backbone geometry.\n    *   **Typical threshold:** A backbone (or Cα) RMSD of **<1.0–1.5 Å** generally indicates a well-preserved fold. Values >2.0 Å often suggest significant structural deviation.\n*   **Alternative/complementary metrics:** TM-score or GDT-TS for longer peptides, which are more global measures of fold similarity.", "latency_ms": 20766, "timestamp": "2026-02-09T12:36:11.446797+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|OPT-PEP-03", "question_id": "OPT-PEP-03", "pair_id": "OPT-03", "category": "Optimization Approaches", "domain": "peptide", "question_text": "In phage display affinity maturation, name two experimental knobs that increase selection stringency across rounds and explain the expected effect on the enriched pool.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "In phage display affinity maturation, two key experimental knobs to increase selection stringency across rounds are:\n\n1. **Reducing the concentration of the target antigen during panning**  \n   - **Effect**: Lower antigen concentration limits binding sites, favoring phages with higher affinity and slower off-rates. This enriches the pool for clones with improved binding constants (e.g., lower \\( K_d \\) values, often in the nanomolar to picomolar range after maturation).\n\n2. **Increasing the number or duration of wash steps**  \n   - **Effect**: Harsher washes remove weakly bound phages, selecting for variants with strong, stable interactions. This reduces background and enriches the pool for high-affinity binders with reduced dissociation rates.\n\nAdjusting these parameters across rounds progressively eliminates low-affinity binders, leading to a pool dominated by high-affinity variants.", "latency_ms": 15053, "timestamp": "2026-02-09T12:36:29.500138+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|SAR-SM-02", "question_id": "SAR-SM-02", "pair_id": "SAR-02", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A carboxylate on a small molecule forms a salt bridge to a Lys side chain (N–O distance ~2.8–3.0 Å) and is required for activity. What is the most likely effect on potency if you convert the carboxylic acid to a methyl ester, and why?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Converting the carboxylic acid to a methyl ester will likely cause a substantial decrease in potency. This is because the methyl ester is uncharged at physiological pH, eliminating the ability to form the essential salt bridge with the positively charged lysine side chain. Salt bridges typically contribute 1–3 kcal/mol of binding energy, so losing this interaction can reduce affinity by 10- to 100-fold or more, directly impairing activity.", "latency_ms": 17694, "timestamp": "2026-02-09T12:36:50.195089+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|OPT-PEP-09", "question_id": "OPT-PEP-09", "pair_id": "OPT-09", "category": "Optimization Approaches", "domain": "peptide", "question_text": "A baseline peptide has Kd = 1.0 µM. Mutation A gives Kd = 0.30 µM, mutation B gives Kd = 0.20 µM, and double mutant AB gives Kd = 0.020 µM. Under a multiplicative (log-additive) model, what Kd would you predict for AB, and does the result indicate synergy?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Under a multiplicative (log-additive) model, the predicted Kd for the double mutant AB is 0.06 µM, calculated as the product of the individual mutation effects relative to the baseline: (0.30 × 0.20) × 1.0 µM = 0.06 µM. The observed Kd of 0.020 µM is lower than predicted, indicating synergistic effects between the mutations.", "latency_ms": 29290, "timestamp": "2026-02-09T12:37:22.486271+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|OPT-PEP-02", "question_id": "OPT-PEP-02", "pair_id": "OPT-02", "category": "Optimization Approaches", "domain": "peptide", "question_text": "Define a Pareto-optimal set for peptides optimized simultaneously for higher potency, higher serum stability, and lower hemolysis. What does it mean for one peptide to dominate another?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "In multi-objective optimization of peptides for higher potency, higher serum stability, and lower hemolysis, the **Pareto-optimal set** consists of all peptide candidates for which no other peptide exists that is at least as good in all three objectives and strictly better in at least one. This set represents the best possible trade-offs among the conflicting objectives.\n\n**Domination** means that one peptide (A) dominates another (B) if:\n- Potency(A) ≥ Potency(B) (higher is better),\n- Serum stability(A) ≥ Serum stability(B) (higher is better),\n- Hemolysis(A) ≤ Hemolysis(B) (lower is better),\nwith at least one inequality being strict (e.g., strictly higher potency or lower hemolysis). If A dominates B, B is not Pareto-optimal, as A is superior without sacrificing any objective.", "latency_ms": 20481, "timestamp": "2026-02-09T12:37:45.967622+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|OPT-SM-09", "question_id": "OPT-SM-09", "pair_id": "OPT-09", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "A baseline inhibitor has IC50 = 1.0 µM. Substitution A gives IC50 = 0.30 µM, substitution B gives IC50 = 0.20 µM, and the double substitution AB gives IC50 = 0.020 µM. Under a multiplicative (log-additive) model, what IC50 would you predict for AB, and does the observation indicate positive epistasis (synergy)?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Under a multiplicative model, the predicted IC50 for AB is 0.060 µM (calculated as 1.0 µM × (0.30/1.0) × (0.20/1.0) = 0.060 µM). The observed IC50 of 0.020 µM is lower than predicted, indicating positive epistasis (synergy), as the combined effect exceeds the log-additive expectation.", "latency_ms": 12516, "timestamp": "2026-02-09T12:38:01.484087+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|GEN-SM-10", "question_id": "GEN-SM-10", "pair_id": "GEN-10", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "You expand a molecular generator to include non-standard charged fragments (new tokens not seen in the original training set). What two components must be updated to keep generation chemically consistent and valid?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "To maintain chemical consistency and validity when expanding a molecular generator with non-standard charged fragments (new tokens), two key components must be updated:\n\n1. **Token Vocabulary/Tokenizer**: The set of allowable tokens must be extended to include representations of the new charged fragments, enabling the generator to recognize and use them during sequence generation (e.g., in SMILES or SELFIES strings).\n\n2. **Chemical Rule Set/Validity Checker**: The rules or constraints that enforce chemical validity—such as valency, charge balance, bonding patterns, and stability—must be updated to account for the specific properties and behaviors of the charged fragments, ensuring generated molecules are syntactically and semantically correct.", "latency_ms": 27701, "timestamp": "2026-02-09T12:39:10.099450+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|SAR-SM-07", "question_id": "SAR-SM-07", "pair_id": "SAR-07", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A phenyl ring in a lead compound occupies a hydrophobic pocket in both the intended target and a close off-target homolog. Only the intended target has a nearby Ser OH positioned to hydrogen-bond to a ring heteroatom. What is the expected effect on target potency and selectivity of replacing phenyl with a 3-pyridyl ring (introducing one ring nitrogen), and why?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Replacing phenyl with 3-pyridyl is expected to increase potency for the intended target and enhance selectivity over the off-target homolog. \n\n- **For the intended target:** The 3-pyridyl nitrogen acts as a hydrogen bond acceptor, forming a favorable interaction with the nearby Ser OH. This additional polar interaction improves binding affinity.\n- **For the off-target:** Lacking the Ser OH, the polar nitrogen disrupts hydrophobic packing in the pocket without compensatory interactions, reducing binding affinity.\n\nThus, the modification leverages the unique serine residue in the intended target to achieve both higher potency and greater selectivity.", "latency_ms": 24078, "timestamp": "2026-02-09T12:39:37.178451+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ASSAY-PEP-09", "question_id": "ASSAY-PEP-09", "pair_id": "ASSAY-09", "category": "Assay Interpretation", "domain": "peptide", "question_text": "Protease degradation of a peptide shows biphasic kinetics: 60% loss in the first 10 minutes, then slow decay over the next 2 hours. Give one kinetic explanation and one experiment that tests it.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "", "latency_ms": 25555, "timestamp": "2026-02-09T12:42:47.309950+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "deepseek-v3.2:cloud|ASSAY-PEP-03", "question_id": "ASSAY-PEP-03", "pair_id": "ASSAY-03", "category": "Assay Interpretation", "domain": "peptide", "question_text": "An antimicrobial peptide has MIC = 2 µg/mL against a bacterium and hemolysis HC50 = 200 µg/mL. Compute the therapeutic index (HC50/MIC) and interpret it.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "The therapeutic index (TI) is calculated as HC50/MIC = 200 µg/mL ÷ 2 µg/mL = **100**.\n\nInterpretation: A TI of 100 indicates that the peptide requires a concentration 100 times higher to cause hemolysis in 50% of red blood cells than to inhibit bacterial growth. This suggests a wide safety margin and good selectivity for bacterial cells over mammalian cells, making it a promising candidate for therapeutic development. However, the therapeutic index is an in vitro measure and does not account for pharmacokinetics or dynamic physiological conditions.", "latency_ms": 6538, "timestamp": "2026-02-09T12:42:56.848345+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|GEN-PEP-04", "question_id": "GEN-PEP-04", "pair_id": "GEN-04", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "Phage display yields enrichment values across panning rounds. How can enrichment be used as a training signal for peptide sequence generation, and what experimental bias must be considered?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Enrichment values from phage display panning rounds can be used as a training signal for peptide sequence generation in machine learning models by treating them as a proxy for binding affinity or fitness. The process typically involves:\n\n1. **Training Signal Definition**: The enrichment ratio (e.g., output/input phage titer per round or frequency increase across rounds) for each sequenced peptide is used as a continuous label. This enables supervised learning to map peptide sequences to their relative binding scores.\n\n2. **Model Application**: Models (e.g., regression models, neural networks, or generative adversarial networks) are trained to predict enrichment from sequence features. Alternatively, reinforcement learning can use enrichment as a reward signal to guide sequence generation toward higher-binding variants.\n\n3. **Goal**: The model learns the sequence-function relationship to generate novel peptides with predicted high enrichment, accelerating discovery beyond the screened library.\n\n**Key experimental biases to consider**:\n- **Amplification Bias**: Differential phage propagation rates during bacterial amplification can skew sequence representation independent of binding.\n- **Selection Stringency**: Overly stringent washing may eliminate weak binders entirely, compressing the dynamic range of enrichment values.\n- **Library Diversity Limitations**: Initial library biases (e.g., codon usage, length variation) may cause spurious correlations.\n- **PCR and Sequencing Errors**: Artifacts introduced during sample preparation can generate false sequences or frequency distortions.\n- **Non-specific Binding**: Peptides binding to non-target components (e.g., well plates, beads) yield false-positive enrichment.\n\nTo mitigate these, controls (e.g., counter-selection, deep sequencing of input libraries) and normalization strategies (e.g., correcting for amplification bias via control panning) are essential before using data for training.", "latency_ms": 14230, "timestamp": "2026-02-09T12:43:14.079383+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|GEN-PEP-10", "question_id": "GEN-PEP-10", "pair_id": "GEN-10", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "You expand a peptide generator to include several non-natural amino acids. What must be updated in the model representation and in downstream scoring to keep generation physically and chemically coherent?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "To maintain physical and chemical coherence when expanding a peptide generator to include non-natural amino acids, updates are required in both model representation and downstream scoring:\n\n### Model Representation Updates:\n1. **Token Expansion**: Extend the model's vocabulary to include unique tokens for each non-natural amino acid (e.g., adding symbols like \"Aib\" for α-aminoisobutyric acid).\n2. **Feature Engineering**: Update input feature vectors to incorporate physicochemical properties of non-natural amino acids (e.g., hydrophobicity, charge, side-chain volume). For example, include calculated logP values or Hansen solubility parameters if previously used for natural amino acids.\n3. **Embedding Adaptation**: If using embedding layers, retrain or initialize embeddings to capture chemical similarities, possibly using pre-trained representations from molecular fingerprints or quantum chemical descriptors.\n4. **Structural Constraints**: Integrate chirality and bond geometry rules to prevent generation of sterically impossible conformations (e.g., disallow D-amino acids in positions that disrupt helical handedness without proper context).\n\n### Downstream Scoring Updates:\n1. **Property Predictors**: Recalibrate or retrain predictive models for properties like solubility, stability, and bioactivity to include non-natural amino acids. For instance,", "latency_ms": 24027, "timestamp": "2026-02-09T12:43:41.107417+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|SAR-SM-10", "question_id": "SAR-SM-10", "pair_id": "SAR-10", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A biaryl inhibitor rapidly interconverts between two atropisomers, but only one atropisomer fits the binding pocket. What design change is most likely to increase potency and selectivity, and why?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "To increase potency and selectivity, introduce steric hindrance ortho to the biaryl bond (e.g., with bulky substituents) to raise the rotational barrier and lock the compound in the bioactive atropisomeric conformation. This ensures that all molecules are in the binding-competent form, increasing effective concentration and potency. Selectivity improves because the locked conformation reduces the ability to adapt to off-target binding pockets.", "latency_ms": 18823, "timestamp": "2026-02-09T12:44:02.931193+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ASSAY-PEP-05", "question_id": "ASSAY-PEP-05", "pair_id": "ASSAY-05", "category": "Assay Interpretation", "domain": "peptide", "question_text": "In a mouse efficacy study of a therapeutic peptide dosed weekly, efficacy improves on days 1–3 but wanes by week 3 despite unchanged dosing. Give two plausible assay-linked explanations and name one measurement that distinguishes them.", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Two plausible assay-linked explanations are:  \n1. **Development of anti-drug antibodies (ADAs)** – Repeated dosing may induce an immune response, leading to antibodies that neutralize the peptide or increase its clearance, reducing efficacy over time.  \n2. **Assay interference from metabolites or matrix effects** – Accumulating peptide metabolites or changes in biological samples (e.g., serum components) may interfere with the assay's detection, causing an apparent decline in efficacy even if the peptide remains active.\n\nOne measurement that distinguishes them is **quantifying peptide plasma concentrations using a specific, interference-free method like LC-MS/MS**. If plasma levels decrease over time, it supports ADA-mediated clearance; if levels remain stable, it suggests assay interference.", "latency_ms": 22451, "timestamp": "2026-02-09T12:45:43.277677+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|ADMET-SM-09", "question_id": "ADMET-SM-09", "pair_id": "ADMET-09", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "How do you experimentally distinguish reversible CYP inhibition from mechanism-based (time-dependent) inhibition in vitro, and why does time-dependent inhibition elevate clinical DDI risk?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "To distinguish reversible from mechanism-based (time-dependent) CYP inhibition in vitro, the key experiment is a **two-step pre-incubation assay** comparing IC₅₀ values with and without NADPH cofactor during pre-incubation.\n\n**Experimental Protocol:**\n1. **Pre-incubation step:** Incubate the inhibitor with human liver microsomes (or recombinant CYP) **with NADPH** (to allow metabolic activation) for ~30 minutes.\n2. **Dilution step:** Dilute the mixture (typically 10-fold) into a secondary incubation containing the CYP probe substrate and NADPH to measure residual enzyme activity.\n3. **Control conditions:** Run parallel experiments (a) without NADPH during pre-incubation, and (b) without pre-incubation (direct incubation of inhibitor with substrate and NADPH).\n\n**Key Distinguishing Observations:**\n- **Reversible inhibition:** IC₅₀ remains similar regardless of pre-incubation. Dilution often restores enzyme activity.\n- **Time-dependent inhibition (TDI):** IC₅₀ **shifts left** (potency increases, often ≥10-fold) after pre-incubation with NADPH. Activity loss persists after dilution due to irreversible or quasi-irreversible enzyme inactivation.\n\n**Supporting assays:** Assess **time- and concentration-dependent** enzyme inactivation kinetics (Kᵢ and kᵢₙₐₐ). TDI shows characteristic saturation kinetics with increasing inhibitor concentration.\n\n---\n\n**Why TDI elevates clinical DDI risk:**\n1. **Irreversible enzyme depletion:** Inactivation requires synthesis of new enzyme (turnover half-life ~24-72h for CYPs), causing prolonged effects even after inhibitor discontinuation.\n2. **Non-competitive kinetics:** DDI magnitude depends on inactivation rate (kᵢₙₐₐ) and enzyme degradation rate (kₑₗ), not just reversible binding affinity.\n3. **Predictive challenges:** Maximal DDI may occur after multiple doses, unlike reversible inhibition where risk is highest at peak plasma concentration.\n4. **Hepatic concentration effects:** Reactive metabolites may accumulate in hepatocytes, increasing inactivation beyond predictions from circulating inhibitor concentrations.\n\nThis explains why TDI compounds (e.g., paroxetine for CYP2D6, erythromycin for CYP3A4) often require stringent clinical DDI management despite modest reversible inhibition potency.", "latency_ms": 16412, "timestamp": "2026-02-09T12:46:02.689992+00:00", "success": true, "error": null}
{"response_id": "deepseek-v3.2:cloud|SAR-SM-03", "question_id": "SAR-SM-03", "pair_id": "SAR-03", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A ligand has a flexible linker (6 rotatable bonds) between two pharmacophoric groups. A co-crystal shows the bound conformation is U-shaped, but in solution the ligand is highly flexible. What is the most likely effect of macrocyclizing the linker to bias the U-shape, and why?", "model": "DeepSeek V3.2", "model_tag": "deepseek-v3.2:cloud", "response_text": "Macrocyclization to pre-organize the U-shaped conformation will most likely **improve binding affinity (lower Kd), primarily by reducing the unfavorable entropy loss (ΔS) upon binding.**\n\n**Why:**\n1.  **Entropic Penalty:** In solution, the flexible linker (6 rotatable bonds) samples many conformations. Upon binding to the rigid U-shape, the ligand loses significant conformational entropy, which is thermodynamically unfavorable. Each rotatable bond frozen upon binding typically contributes an entropic penalty of ~0.5 to 1.5 kcal/mol.\n2.  **Pre-organization:** The macrocycle restricts the linker's flexibility, biasing it toward the bioactive U-shape. This means the ligand loses less conformational entropy when it binds because it is already in (or near) the correct conformation.\n3.  **Thermodynamic Outcome:** The binding free energy equation is ΔG = ΔH - TΔS. Macrocyclization primarily makes ΔS less negative (or more positive), thus making ΔG more negative (stronger binding). The enthalpic contribution (ΔH) from the ligand-target interactions may remain largely similar, as the pharmacophores engage the same way.\n\n**Expected Effect Magnitude:** The affinity improvement is often in the range of **10 to 100-fold** (≈1.4 to 2.7 kcal/mol), depending on the specific system, due to the removal of entropic penalty from several rotatable bonds.\n\n**Caveat:** This assumes the macrocycle introduces minimal strain and does not disrupt key interactions. If the macrocycle is overly strained or mispositions the pharmacophores, affinity could decrease.", "latency_ms": 20217, "timestamp": "2026-02-09T12:46:25.908066+00:00", "success": true, "error": null}
